Introduction {#s1}
============

Gene expression is the central process that drives all other cellular processes required for life. The amounts and modification states of the mRNA and protein gene products are what ultimately determine the identity, function and fate of a given cell. The abundances of both mRNAs and proteins are in turn determined kinetically by balancing both synthetic and degradative processes. At the mRNA level, we have a detailed understanding of both how mRNAs are made and how the individual steps of transcription, splicing and maturation are regulated. However, less is known about the regulation of mRNA decay. Whereas individual steps of mRNA degradation have been determined, the question of what determines the stability of mRNAs across the transcriptome remains largely unanswered.

Bulk mRNA degradation was shown to be initiated by the removal of the polyA tail ([@bib61]; [@bib40]). This triggers degradation through one of two pathways. mRNAs can either be degraded from the 3' end by the exosome complex of 3' to 5' exonucleases or -what is thought to be more common in yeast- deadenylation is followed by removal of the 5'-methylguanosine cap by the decapping complex ([@bib39]; [@bib13]). Removal of the cap structure is then followed by exonucleolytic digestion from the 5' end of the mRNA by the cytoplasmic 5' to 3' exonuclease, Xrn1. While these pathways of mRNA degradation are well elucidated, their upstream regulators remain less clear and it is not well understood how the decision is made whether an mRNA continues to be translated or enters the decay pathway.

Factors ranging from polyA tail length to mRNA structure have been proposed to affect global transcript stability but many models have been centered on how the process of translation regulates transcript lifetime. Two alternative models have been put forth to explain how mRNA decay is linked to translation (Figure 3A). The first model originates from the observation that mRNA stability significantly correlates with codon usage. It was proposed that slowly elongating ribosomes at suboptimal codons signal to the decay machinery to target the bound mRNAs for destruction. Therefore, this stalled ribosome-triggered decay model centers on the process of translation elongation ([@bib51]; [@bib52]). The second model arises from the observations that translation and decay are inversely related and posits that bound translation factors protect an mRNA from decay. Such a translation factor-protection model predicts that translation initiation, either directly or indirectly, competes with the RNA decay machinery. In the latter model, the stability of a given transcript would be determined by a competition between the eIF4F initiation complex and the decapping complex for the 5' methylguanosine cap, and/or by ribosomes sterically blocking decay factors from the mRNA ([@bib2]; [@bib55]; [@bib56]; [@bib31]). Both of these models have supporting experimental evidence and are also not mutually exclusive. However, the available experimental evidence for each of these models has mainly been gathered using specific reporter transcripts and methods to measure mRNA stability that can introduce unintended effects and thus might lead to non-physiological measurements of half-life as discussed below. Moreover, the perturbations that have been employed to probe the relationship between translation and decay have the potential for significant secondary effects. Thus, improved methods to both measure mRNA stability as well as perturbing core elements of the translation machinery are required to evaluate the existing models.

Classical measurements of mRNA stability for multiple transcripts in parallel have employed global inhibition of transcription. This leads to two major complications. The first is that the global inhibition of transcription is a major perturbation to the cell and this has been shown to induce a general stress response ([@bib63]). This stress response is elicited regardless of the method of global transcription inhibition be it by pharmacological or genetic means. The second complication arises from the fact that the methods used to shutoff transcription have off-target effects themselves. Temperature shock or the use of transcriptional inhibitors such as phenantroline and thiolutin have unintended effects on cell physiology independent of transcriptional inhibition ([@bib63]; [@bib23]). At the individual transcript measurement level, the use of transcriptional shutoff via the regulatable *GAL* promoter has also been widely used. However, shutoff of the *GAL* promoter requires an acute carbon source shift and it has been shown that several key factors in the decay pathway such as Pat1, Dhh1, Ccr4 and Xrn1 are regulated in a carbon source-dependent manner ([@bib53]; [@bib5]).

In this study, we have sought to determine how mRNA half-life is controlled on a transcriptome-wide level and have taken a two-pronged approach to study the relationship between translation and decay. First, we refine a metabolic labeling-based assay to measure mRNA lifetimes in a transcriptome-wide and non-invasive manner. Our new measurements reveal a much more dynamic transcriptome than previously measured by metabolic labeling with an average and median transcript half-life of only 4.8 and 3.6 min respectively. Next, we combine this measurement tool with both pharmacological and conditional genetic tools to directly perturb the processes of translation initiation and elongation. Our studies show that the competition between translation initiation and mRNA turnover determines the lifetime for an mRNA whereas slowing elongation globally leads to mRNA stabilization. At the cellular level, we find that the formation of processing bodies, sites where mRNAs are thought to be repressed and destroyed, is stimulated when translation initiation is attenuated suggesting that processing bodies form when mRNA clients are shunted into the degradation pathway.

Results {#s2}
=======

An improved non-invasive metabolic labeling method reveals that the yeast transcriptome is highly unstable {#s2-1}
----------------------------------------------------------------------------------------------------------

We and others previously demonstrated that thio-modified uracil nucleobases, such as 4-thio-uracil (4TU) are efficiently incorporated into nascent RNA ([@bib41]; [@bib37]; [@bib12]; [@bib14]). Metabolic labeling with 4TU at appropriate concentrations has no adverse effect on cell proliferation and does not lead to major changes in gene expression ([@bib63]; [@bib37]) (see Appendix 1). Taking advantage of the thio-reacting group, labeled RNAs can then be biotinylated allowing for an affinity-based separation of thio-labeled mRNAs from unlabeled mRNAs in pulse-labeling experiments ([Figure 1A](#fig1){ref-type="fig"}). When this strategy is applied in a time-resolved manner, it enables the direct measurement of mRNA decay kinetics in an unperturbed system.

![Improved mRNA stability measurements with metabolic labeling.\
(**A**) Experimental scheme to measure mRNA stability and production by metabolic labeling. (**B**) Wild-type cells (KWY165) were subjected to the experiment described in (**A**) and decay rates for *ACT1*, *CIS3* and *RPL25* transcripts were determined by RT-qPCR. (**C**) mRNA samples in (**B**) were quantified by RNA-seq to determine mRNA stabilities across the transcriptome. Half-lives are plotted by frequency and each bin is 0.5 min wide.\
10.7554/eLife.32536.005Figure 1---source data 1.Source data for [Figure 1B](#fig1){ref-type="fig"}: decay kinetics of ACT1, CIS3 and RPL25 mRNAs.\
10.7554/eLife.32536.006Figure 1---source data 2.Source data for [Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}: transcriptome wide decay data for two biological replicates of wild-type yeast cells grown in exponential phase.](elife-32536-fig1){#fig1}

We made three key modifications to our previously published protocol ([@bib41]). All modifications targeted the problem of inefficient subtraction of newly synthesized mRNAs, which can result from inefficient chase of a metabolic label or low enrichment for labeled RNA during biotin-mRNA separation (see Appendix 1 for a detailed discussion). First, we optimized streptavidin-bead blocking and washing conditions that significantly reduced non-specific RNA bead binding ([Figure 1A](#fig1){ref-type="fig"}, step 6). Notably, the extent of non-specific bead binding differed between mRNAs indicating that non-specific binding can cause transcript-specific as well as global errors in decay rate determination. Second, we switched to the recently developed MTSEA-biotin which crosslinks biotin to a free thio group with far greater efficiency than the previously used HPDP-biotin ([@bib16]) ([Figure 1A](#fig1){ref-type="fig"}, step 4). In combination, this improved efficiency allowed us to employ a 4TU)-chase labeling scheme in which rates of transcription and decay can be measured simultaneously ([Figure 1A](#fig1){ref-type="fig"}). Lastly, we simulated the effect that inefficiency would generally have on decay data and found that by introducing an efficiency parameter into the standard exponential decay model, we were able to account for the remaining inefficiency in labeling and capture while extracting the essential stability parameters from the data ([Appendix 1---figure 10](#app1fig10){ref-type="fig"}, [Figure 1B](#fig1){ref-type="fig"}). This modification of the standard exponential decay model allows one to account for the general experimental problem of inefficiency in mRNA labeling (due to uracil content and overall thio-uracil uptake), biotin crosslinking (thio-uracils that remain uncrosslinked to biotin) and biotinylated RNA separation (due to transcript-specific issues of bead and tube retention) (materials and methods).

Using this protocol, we measured half-life values for 5378 of the 6464 annotated transcripts in rapidly dividing budding yeast with a high agreement between biological replicates (Pearson correlation = 0.90) ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). The analysis of the efficiency parameter showed that 92% of transcripts are labeled and separated with \>90% efficiency and 98% of transcripts are labeled and separated with \>80% efficiency indicating that our experimental optimizations are performing well ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). Moreover, our data displayed a good fit to our modified exponential decay model with 84% of transcripts fitting with an R^2^ of \>0.95 ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). Of the remaining transcripts, 209 fit the model poorly (R^2^ \<0.8) and an additional 877 could not be fit ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Most of these latter transcripts showed very low expression in our growth conditions and were thus excluded from the analysis.

The new measurements with our improved protocol revealed a much less stable transcriptome than previously reported, with average and median mRNA half-lives of 4.8 and 3.6 min respectively ([Figure 1C](#fig1){ref-type="fig"}). By summing the abundance of all mRNAs, we calculated the half-life of the bulk transcriptome to be 13.1 min ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Note that this value is higher than the 4.8 min average value because it takes into account transcript abundance and many of the longest-lived transcripts are present in many copies within the mRNA pool. Previously, the stability of the polyA(+) RNA pool had been measured by ^14^C-adenine pulse-labeling experiments, which are the least invasive measurements that have been performed to date and could be considered the benchmark to evaluate any mRNA stability determining method. Our measurement using thio-uracil chase agrees remarkably well with ^14^C-adenine pulse labeling data which reported a 11.5 min half-life for the bulk polyA(+) RNA pool in the cell ([@bib50]).

We also profiled the stability of the transcriptome in the absence of polyA selection by sequencing unselected, total RNAs after metabolic labeling. We found that the overall stabilities were similar: in the absence of polyA selection, the average and median mRNA half-lives were 4.9 and 4.0 min respectively compared to 4.8 and 3.6 min with polyA selection ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). The correlation between half-lives measured by these two datasets was only 0.44, which is likely due to the low number of mRNA reads recovered from the total RNA reads (0.8--2.5% of total reads depending on the timepoint) when total RNA was sequenced ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}). Accordingly, many lower correlating transcripts were of low abundance and correlation increased amongst the higher abundance transcripts when half-lives derived from polyA selection were compared to unselected RNA. ([Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}). However, for specific transcripts, biological differences in mRNA decay steps downstream of deadenylation such as decapping and exo-nucleolytic processing probably also contribute to the differences between the two measurements. Nevertheless, we conclude that the overall stability of the transcriptome remains largely unchanged in the absence of polyA selection indicating that for the majority of transcripts, deadenylation is the rate determining step for decay.

Consistent with the extensive protocol optimization, we found an overall poor correlation with our previously published dataset ([Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}). Nonetheless, our current measurements are consistent with the findings of Munchel et al. that long-lived (\>1 SD above the mean) transcripts are functionally enriched for translation factors and that ribosomal protein-encoding mRNAs specifically are long lived as a group with an average half-life of 15.5 min ([Figure 1---figure supplement 1.G](#fig1s1){ref-type="fig"}; [Figure 1---figure supplement 1.H](#fig1s1){ref-type="fig"}) ([@bib41]). There is no significant functional enrichment in genes with exceptionally short (\<1 SD below the mean) mRNA half-lives. Our dataset does not agree well with the datasets derived from global transcriptional inhibition, which cluster with each other ([@bib23])([Figure 1---figure supplement 1I](#fig1s1){ref-type="fig"}). This is consistent with the findings of Sun et al. and Harigaya et al. that methods relying on transcriptional inhibition all induce a global stress response that is elicited regardless of the method of transcriptional inhibition ([@bib63]; [@bib23]). Instead, our dataset clusters with the datasets of Cramer and Gresham that also employed non-invasive metabolic labeling although the transcriptome is much less stable by our measurements ([Figure 1---figure supplement 1I](#fig1s1){ref-type="fig"}) ([@bib63]; [@bib37]; [@bib43]). This shorter half-life of the transcriptome is likely due to improvements in biotin-crosslinker technology, the inclusion of multiple timepoints in rate determination, cleaner methods for separating biotinylated-RNAs from unlabeled RNAs as well as improvements to the modeling and extraction of half-life parameters from the decay measurements. The overall distribution of half-lives for all fitted mRNAs ([Figure 1C](#fig1){ref-type="fig"}) is non-Gaussian stretching across more than an order of magnitude. The shortest half-lives are less than 1 min whereas the most stable transcripts have half-lives of more than 30 min.

Slowing translation elongation protects transcripts against degradation {#s2-2}
-----------------------------------------------------------------------

To begin to identify factors that regulate this half-life diversity, we compared our decay dataset to other transcriptome-wide datasets of various mRNA measurements ([Figure 2](#fig2){ref-type="fig"}). Our decay data clustered with transcript abundance, metrics of codon usage (normalized translational efficiency (nTE) and codon adaptation index (CAI)), as well as translational efficiency measured by ribosome footprinting ([@bib46]; [@bib15]). The positive relationship between abundance and half-life supports the notion that mRNA levels are not only primarily dictated by the rate of synthesis, but that differential mRNA stability contributes to the regulation of transcript abundance as well. Interestingly, mRNA half-life was negatively correlated with polyA-tail length consistent with prior observations (see discussion) ([@bib62]).

![Correlation of mRNA features.\
(**A**) Spearman rank correlation coefficients were computed for pairs of mRNA parameters of stability (half-life), translation efficiency (TE), polyA tail length, codon optimality (CAI), tRNA optimality (nTE), abundance, UTR lengths, GC content and ORF length and plotted as a heatmap. Datasets were hierarchically clustered based on Euclidian distances. Orange represents positive correlation and blue represents negative correlation. Correlations between identical datasets are colored in gray. See [Supplementary file 1](#supp1){ref-type="supplementary-material"} for sources of genome wide data.](elife-32536-fig2){#fig2}

Our correlation analyses support prior work pointing to mRNA translation efficiency as a critical determinant of mRNA half-life. The aforementioned stalled ribosome-triggered decay and translation factor-protection models attempt to explain the positive correlations between mRNA half-life and codon usage and mRNA half-life and translation efficiency respectively ([Figure 3A](#fig3){ref-type="fig"}). These two models make clear and opposing predictions for how perturbing the processes of translation elongation or initiation impacts transcript stability. The stalled ribosome-triggered decay model predicts that mRNAs are destabilized upon slowing elongation whereas the translation factor-protection model predicts the opposite since slowly elongating ribosomes would accumulate on a given transcript and thus provide greater steric exclusion of decay factors. In contrast, when translation initiation rates are attenuated, the stalled ribosome-triggered decay model predicts that transcripts would either have the same stability or possibly even increased stability as once the bound ribosomes complete translation, the naked mRNA would be freed from decay-triggering ribosomes. The translation factor-protection model again predicts the opposite outcome: decreasing the rate at which translation is initiated leaves the 5' cap more exposed to the decapping machinery and fewer loaded ribosomes allows the decay factors greater access to the transcript culminating in an overall decrease in transcript stability.

![mRNAs are stabilized by slowly elongating ribosomes and destabilized when translation initiation is inhibited.\
(**A**) Cartoon depictions of the stalled ribosome-triggered decay and translation factor-protection models. (**B**) Wild-type cells (KWY165) were subjected to mRNA stability profiling immediately after addition of 0.1% DMSO or 0.2 μg/mL cycloheximide in 0.1% DMSO. Data on *ACT1*, *CIS3* and *RPL25* mRNAs were collected and plotted. See [Figure 3---figure supplement 4A](#fig3s4){ref-type="fig"} for biological replicates. P-values are computed using a one-sided paired t-test for both the stalled ribosome-triggered decay model (p(SR)) as well as the translation factor-protection model (p(TP)). P-values less than 0.05 are significant. (**C**) Wild-type cells (KWY165) were subjected to mRNA stability profiling 33 min after addition of 0.1% ethanol or 1.5 μg/mL sordarin in 0.1% ethanol (note that this is the timepoint when a growth defect is manifested, see [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). Data were collected, analyzed and plotted as in [Figure 3B](#fig3){ref-type="fig"}. See [Figure 3---figure supplement 4B](#fig3s4){ref-type="fig"} for biological replicates. (**D--G**) *HIS3 gcn2∆* cells (KWY7337) were subjected to mRNA stability profiling immediately after non-addition (mock) or addition of 5 mM 3AT. Data were collected, analyzed and plotted as in [Figure 3B](#fig3){ref-type="fig"}. See [Figure 3---figure supplement 4C](#fig3s4){ref-type="fig"} for biological replicates. (**H**) mRNA samples collected from the experiment described in [Figure 3D--G](#fig3){ref-type="fig"} were subjected to global mRNA stability profiling. Cumulative frequencies of transcript half-life are plotted. (**I**) Wild-type cells (KWY165) were subjected to mRNA stability profiling immediately after addition of 0.1% DMSO or 10 μM hippuristanol. Data were collected, analyzed and plotted as in [Figure 3B](#fig3){ref-type="fig"}. p-values were not computed for the stalled ribosome-triggered decay model as this model does not make a clear prediction as to how mRNA stability is affected when translation initiation is perturbed. See [Figure 3---figure supplement 5A](#fig3s5){ref-type="fig"} for biological replicates. (**J**) *pGPD1-LexA-EBD-B112 CDC33-3V5-IAA7* pRS425 cells (KWY7336: control) and *pGPD1-LexA-EBD-B112 CDC33-3V5-IAA7 pGPD1-OsTIR1* pRS425-*p4xLexOcyc1-CDC33^∆CAP^* cells (KWY7334: eIF4E/G^down^) were grown in CSM-LEU-0.5xURA pH5.5 media and subjected to mRNA stability profiling immediately after addition of 10 nM β-estradiol, 100 μM 3-indoleacetic acid and 4 μM IP~6~. Data were collected, analyzed and plotted as in [Figure 3I](#fig3){ref-type="fig"}. See [Figure 3---figure supplement 5B](#fig3s5){ref-type="fig"} for biological replicates. (**K**) Wild-type cells (KWY165) were subjected to global mRNA stability profiling immediately after addition of 0.1% DMSO (gray) or 2.6 μM hippuristanol (orange) or 0.2 μg/mL cycloheximide (blue). Cumulative frequencies of transcript half-life are plotted.\
10.7554/eLife.32536.014Figure 3---source data 1.Source data for [Figure 3B, C, D--G, I and J](#fig3){ref-type="fig"}: decay kinetics of selected mRNAs in cells treated with translational inhibitors.\
10.7554/eLife.32536.015Figure 3---source data 2.Source data for [Figure 3H](#fig3){ref-type="fig"}: Transcriptome wide decay data for cells treated or mock treated with 3AT.\
10.7554/eLife.32536.016Figure 3---source data 3.Source data for [Figure 3K](#fig3){ref-type="fig"}: Transcriptome wide decay data for cells treated with DMSO, cycloheximide or hippuristanol.](elife-32536-fig3){#fig3}

To begin to test these predictions, we directly perturbed the process of translation elongation and observed the effects on mRNA decay. Consistent with previous reports, we found that treating cells with a strong dose (50 μg/mL) of the elongation inhibitor cycloheximide resulted in stabilized *CIS3* and *RPL25* transcripts and had no significant effect on *ACT1* mRNA stability ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) ([@bib2]). A potentially problematic aspect of these experiments is that high doses of cycloheximide completely halt translation thus shutting down a myriad of cellular processes, which in turn could lead to indirect effects. To address this issue, we titrated the amount of cycloheximide to a sub-lethal concentration (0.2 μg/mL) and assayed the effect of this level of elongation inhibition on transcript stability ([Figure 3---figure supplement 2H](#fig3s2){ref-type="fig"}). Even with this low concentration of cycloheximide, the *CIS3* and *RPL25* transcripts remained stabilized and the *ACT1* mRNA again was not significantly affected ([Figure 3B](#fig3){ref-type="fig"}). The effects of cycloheximide on mRNA turnover were specific to elongation inhibition as mRNA half-lives were unchanged in a cycloheximide resistant mutant (*rpl28-Q38K*) ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). We next tested an alternative translation elongation inhibitor, sordarin, which blocks the function of eukaryotic elongation factor 2 ([@bib58]). When cells were treated with a sub-lethal dose of sordarin, we again observed a stabilizing effect on mRNA half-lives ([Figure 3C](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). These stabilization effects were not due to an inability to incorporate 4TU into newly made transcripts as mRNA synthesis rates were not reduced upon treatment with either cycloheximide or sordarin ([Figure 3---figure supplement 1D and E](#fig3s1){ref-type="fig"}). Moreover, these effects were not specific to polyA selection. When these experiments were analyzed using total RNA, mRNAs were stabilized upon elongation inhibition and the half-life differences were unchanged in the case of low cycloheximide or further exaggerated as in the cases of high cycloheximide and sordarin ([Figure 3---figure supplement 3A--C](#fig3s3){ref-type="fig"}). The dramatic increase in mRNA stability in sordarin or high doses of cycloheximide is consistent with previous findings that decapping rather than deadenylation is blocked upon cycloheximide treatment ([Figure 3---figure supplement 3A and C](#fig3s3){ref-type="fig"})([@bib2]). Using a one-sided paired t-test, we find that 5 of the six measurements support the translation factor protection model (p(TP)\<0.05) and none of the measurements support the stalled ribosome protection model (p(SR)\<0.05). We conclude that inhibiting translation elongation stabilizes mRNAs.

While these results demonstrate that a stalled ribosome per se is not sufficient to induce decay, we could not exclude that cycloheximide or sordarin treatment might only poorly imitate slowed ribosomes on non-optimal codons since the acceptor-site of the ribosome remains occupied when these drugs are employed ([@bib54]). To best mimic a non-optimal codon where the acceptor-site would be unoccupied, we treated cells with a sub-lethal dose (5 mM) of 3-amino-1,2,4-triazole (3AT), which results in histidine starvation thus lowering the concentration of histidyl-tRNAs ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}) ([@bib29]). Indeed 3AT has previously been shown to stall ribosomes at histidine codons ([@bib22]). Histidine starvation also affects translation initiation by phosphorylation of eukaryotic initiation factor 2α via the Gcn2 kinase ([@bib25]). In order to examine the effect on translation elongation by 3AT in isolation, all 3AT experiments were thus performed in *gcn2∆* mutant cells. We examined the stability of 15 mRNAs with diverse spacing and position of histidine codons either untreated or treated with 3AT. Of these 15 paired measurements, we found that 11 are significantly stabilized and support the translation factor protection model (p(TP)\<0.05). We find that none of the measurements support the stalled ribosome triggered decay model (p(SR)\<0.05) ([Figure 3D--G](#fig3){ref-type="fig"}). This overall stabilization effect could not be explained by poor 4TU uptake as mRNA synthesis rates were not reduced upon 3AT treatment ([Figure 3---figure supplement 1G](#fig3s1){ref-type="fig"}). Interestingly, transcripts lacking histidine codons were also stabilized, which is consistent with the observation that 3AT limits glycine availability in addition to the depletion of histidine ([@bib67]). Again, we found that these results were recapitulated in the absence of polyA selection suggesting that the effect of 3AT is not limited to deadenylation but apply to steps downstream in mRNA decay as well ([Figure 3---figure supplement 3D](#fig3s3){ref-type="fig"}).

To understand the effect of 3AT on transcript stability at a global scale, we also subjected our samples to transcriptome-wide stability profiling. The stabilizing effects of 3AT that we observed at the single transcript level were also seen in a highly significant manner across the transcriptome (two-sided Wilcoxian paired test: p=1.165e-199) ([Figure 3H](#fig3){ref-type="fig"}). The impact of histidine and glycine content appears to display as a threshold effect and once a critical number of these amino acids was reached (greater than 2), a larger fold increase in half-life was observed ([Figure 3---figure supplement 1H](#fig3s1){ref-type="fig"}). Importantly, these experiments are in line with experiments from the Jacobson group that employed conditional alleles of genes involved in tRNA maturation or aminoacylation and observed stabilization of transcripts when charged tRNA levels were reduced ([@bib49]; [@bib34]). Altogether, we conclude that inhibiting translation elongation by three different methods led to an overall stabilization of mRNAs. These observations are not consistent with the predictions of the stalled ribosome-triggered decay model but instead support a translation factor-protection model.

Inhibition of translation initiation destabilizes individual transcripts {#s2-3}
------------------------------------------------------------------------

We next studied the effects of inhibiting translation initiation on mRNA decay. We first made use of hippuristanol, an inhibitor of eukaryotic initiation factor 4A (eIF4A) ([@bib4]). We observed that *ACT1*, *CIS3* and *RPL25* mRNAs all decayed with faster kinetics when eIF4A was inhibited ([Figure 3I](#fig3){ref-type="fig"}). We also attempted to generate hippuristanol-resistant alleles of the eIF4A encoding genes, *TIF1* and *TIF2,* to test the specificity of hippuristanol, but these mutations (V326I, Q327G and G351T) led to severe cell sickness (data not shown) ([@bib32]). To exclude any potential indirect effects of hippuristanol, we sought alternative means to inhibit translation initiation. Overexpression of a 5'cap-binding mutant of eIF4E (*cdc33-W104F-E105A* henceforth *cdc33^∆CAP^*) using a β-estradiol inducible promoter caused a subtle inhibition of growth ([@bib35]; [@bib45]) ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}). This defect was fully suppressed by introducing in cis the ∆1--35 (henceforth *cdc33^∆G^*) mutation that abolishes eIF4G binding indicating that overexpression of *cdc33^∆cap^* leads to a dominant-negative loss of eIF4G function likely through a sequestration mechanism ([Figure 3---figure supplement 2A C](#fig3s2){ref-type="fig"}) ([@bib20]). In addition, we placed eIF4E under control of an auxin-inducible degron system (*CDC33-3V5-IAA7*) ([@bib44]). This approach alone led to a mild growth defect upon the addition of auxin presumably because eIF4E could not be fully depleted ([Figure 3---figure supplement 2D--F](#fig3s2){ref-type="fig"}). However, when these two strategies were combined to simultaneously downregulate eIF4E and eIF4G function, we observed a strong synthetic growth defect ([Figure 3---figure supplement 2G](#fig3s2){ref-type="fig"}). This system thus enabled us to acutely inhibit initiation in a manner orthogonal to hippuristanol and evaluate the resulting effects on mRNA decay. As with hippuristanol-treated cells, we found that *ACT1* and *CIS3* transcripts were significantly destabilized while the *RPL25* transcript was not significantly affected when translation initiation is slowed ([Figure 3J](#fig3){ref-type="fig"}). This effect was independent of polyA selection, and as for our experiments where we slowed translation elongation, we obtained comparable results when a polyA selection step was omitted ([Figure 3---figure supplement 3E--F](#fig3s3){ref-type="fig"}). Based on the results of two independent experimental approaches we conclude that inhibiting translation initiation leads to accelerated mRNA decay.

Translation elongation and initiation globally affect mRNA half-lives {#s2-4}
---------------------------------------------------------------------

To test the generality of our findings, we also performed transcriptome-wide mRNA stability profiling of cells treated with either cycloheximide or hippuristanol. To allow for a meaningful comparison, we used hippuristanol at a sub-lethal concentration that confers a near identical growth defect as our sub-lethal concentration of cycloheximide ([Figure 3---figure supplement 2H](#fig3s2){ref-type="fig"}). In support of our observations with individual mRNAs, cycloheximide induced a global stabilization of mRNAs (p=6.298e-106 two-sided Wilcoxon paired test) whereas hippuristanol treatment led to shorter mRNA half-lives (p=1.864e-260 two-sided Wilcoxon paired test) ([Figure 3K](#fig3){ref-type="fig"}). Importantly, the Spearman rank correlation coefficient between these datasets was high (R~sp~(DMSO:HIP)=0.81 and R~sp~(DMSO:CHX)=0.79). This suggests that these drugs did not result in a reordering of the stability profile of the transcriptome or differentially affect specific classes of mRNAs. Instead, this indicates that the drugs generally shifted the profile towards more (cycloheximide) or less (hippuristanol) stable. We conclude that slowing initiation accelerates mRNA turnover while inhibiting elongation slows mRNA turnover and that on a transcriptome-wide level, the efficiency of initiation either directly through 5'-cap competition or indirectly through ribosome protection is a major determinant of transcript stability.

Inhibition of translation initiation induces processing bodies {#s2-5}
--------------------------------------------------------------

What are the consequences of these perturbations to translation and their effect on mRNA decay at the cellular level? Inhibition of elongation with cycloheximide was previously shown to inhibit the formation of processing bodies (PBs), which are thought to be sites of transcript repression and decay ([@bib59]; [@bib30]; [@bib38]). To test the effects of inhibiting translation initiation on PB formation, we treated cells expressing Dhh1-GFP and Dcp2-mCherry markers of PBs with a range of hippuristanol concentrations. Interestingly, hippuristanol induced PB formation in a concentration dependent manner: at high doses (10--40 μM), rapid and robust PB formation could be observed; at an intermediate dose (5 μM), PBs formed over time and at a low dose (2.5 μM), PBs could not be detected ([Figure 4A and B](#fig4){ref-type="fig"}). These observations are consistent with previous reports showing that mutations in eIF3b enhanced PB formation([@bib64]; [@bib7]). Our results show that hippuristanol generates client mRNAs for the decay machinery through its inhibition of initiation. The observed dosage effect therefore suggests that PB formation is directly dependent on the number of mRNA substrates available for degradation and that microscopic PBs can only be detected when a certain threshold of decay targets is reached. Consistent with such a model, we observed the rapid relocalization of three distinct mRNAs, *GFA1*, *PGK1* and *FBA1,* to PBs upon hippuristanol-induced PB formation ([Figure 4D](#fig4){ref-type="fig"}). Unlike in mammalian cell culture systems, hippuristanol does not trigger the formation of stress granules in yeast ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}) but as with other PBs, the formation of hippuristanol-induced Dhh1- and Dcp2-containing foci requires the RNA and ATP binding activities of Dhh1 as mutants of Dhh1 that are unable to bind RNA (*dhh1^3x-RNA^*) or ATP (*dhh1^Q-motif^*) do not form PBs upon hippuristanol treatment ([Figure 4---figure supplement 1B--C](#fig4s1){ref-type="fig"}) ([@bib38]; [@bib36]). An alternate explanation for these hippuristanol-induced PBs is that the perturbation of translation alone may result in cellular stress and PB formation. However, co-treatment of hippuristanol-treated cells with either cycloheximide or sordarin suppressed PB formation, suggesting that the increased number of ribosome-unbound mRNA clients available for degradation, rather than crippled translation, was causative for PB formation ([Figure 4A and C](#fig4){ref-type="fig"}).

![PB formation is stimulated by inhibiting translation initiation and blocked when translation elongation is inhibited.\
(**A**) Dhh1-GFP, Dcp2-mCherry expressing cells (KWY5948) were grown to exponential phase and then treated with 0.1% DMSO, the indicated concentration of hippuristanol or co-treated with the indicated concentration of hippuristanol and either sordarin or cycloheximide. Images were acquired every 5 min using a wide-field microscope and the images were deconvolved. Shown are maximum projections of 8 z-stacks at a distance of 0.4 μm apart. Scale bar: 5 μm. (**B--C**) Number of Dhh1-GFP foci per cell from experiment in (**A**) was counted using Diatrack 2.5 particle tracking software. Error bars represent SEM (n = 3 biological replicates,\>300 cells counted per experiment). (**D**) Dcp2-GFP, PP7CP-mKate2 expressing cells carrying PP7sl tagged copies of *GFA1* (KWY7246), *PGK1* (KWY6963) or *FBA1* (KWY7245) were treated with 40 μM hippuristanol and immediately imaged. Images where acquired every 20 min using a wide-field microscope. Shown are maximum projections of 8 z-stacks at a distance of 0.5 μm apart. Scale bar: 2 μm. (**E**) Dcp2-mCherry, Nup60-3xmKate2, PP7CP-GFP expressing cells carrying a synthetic 3xGST-24xPP7sl under β-estradiol inducible control (KWY7227) were grown to mid-exponential phase, treated with 400 nM β-estradiol for 40 min and then transferred to media lacking β-estradiol and containing 40 μM hippuristanol and immediately imaged (see [Figure 4---figure supplement 1D](#fig1s2){ref-type="fig"} for the no hippuristanol control). Images were acquired every 20 min using a wild-field microscope. Shown are maximum projections of 8 z-stacks at a distance of 0.5 μm apart. Scale bar: 5 μm. For DMSO control images, see [Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}. (**F**) Images acquired in (**E**) were quantified for the colocalization of PP7CP-GFP foci with Dcp2-mCherry foci using FIJI software. Error bars represent SEM (n = 4 biological replicates,\>120 PBs counted per timepoint).\
10.7554/eLife.32536.021Figure 4---source data 1.Source data for [Figure 4B, C and F](#fig4){ref-type="fig"}: accumulation kinetics of P-bodies and decay of RNA in P-bodies in cells treated with translational inhibitors.](elife-32536-fig4){#fig4}

Recent evidence has supported the notion that mRNAs can be degraded in PBs ([@bib38]; [@bib24]). To examine whether we can observe mRNA degradation in PBs that form upon addition of hippuristanol, we placed a model transcript (3xGST) containing PP7 stem loops (PP7sl), which have previously been shown to be slowly decayed, under control of a β-estradiol inducible promoter ([@bib24]). We pulsed cells with this transcript by treating the cells for 40 min with β-estradiol, washed out the inducer, immediately added 40 μM hippuristanol and then observed the localization of the PP7 stem loops over time. As observed for endogenous mRNAs, we found that the PP7sl-containing transcript rapidly localized to PBs ([Figure 4E](#fig4){ref-type="fig"}). Moreover, we found that the PP7-mRNA signal decayed over time within the PB ([Figure 4E and F](#fig4){ref-type="fig"}). This suggests that mRNAs localize to PBs when initiation is inhibited and that these mRNAs can be degraded after they localize to a PB. In combination with our metabolic labeling studies, we further conclude that inhibiting translation initiation leads to global mRNA destabilization which in turn causes the formation of PBs. In the presence of agents that inhibit translation elongation, mRNAs become stabilized reducing the flux of new client mRNAs into the degradation pathway, which in turn suppresses the formation of PBs.

Discussion {#s3}
==========

In this work, we have refined an assay to measure the kinetics of mRNA synthesis and decay based on 4TU metabolic labeling. This approach and similar approaches supersede the traditional methods of transcriptional inhibition as they enable quantitative and global measurements of mRNA kinetics in physiologically unperturbed cells. We used this approach to address the important question of how the process of translation affects transcript stability. Importantly, all of the measurements and experimental perturbations employed here relied on minimally invasive and rapidly inducible methods. Moreover, the drugs we used have specific molecular targets and the genetic inhibitions of eIF4G and eIF4E are induced by hormones from orthologous systems, which have minimal off-target effects.

Taken together, these approaches have enabled us to identify translation initiation as the central hub in globally regulating mRNA stability. While no direct measurement of translation initiation rates at the transcriptome-wide level has been reported, rates estimated by using a kinetic model of ribosome flux ([@bib11]) are in agreement with our conclusion and the dataset of estimated rates strongly correlates and clusters most closely with transcript half-life ([Figure 2---figure supplement 1A--B](#fig2s1){ref-type="fig"}). While we cannot exclude that suboptimal codons enhance the decay of specific transcripts, our results do not support the hypothesis that stalled ribosomes are the primary regulator of cellular mRNA decay on a transcriptome-wide level. Strong evidence for a decay mechanism triggered by sub-optimal codons was derived from experiments employing model transcripts with engineered, de-optimized codon compositions upon transcriptional shut-off ([@bib52]). These experiments are important but they relied on transcriptional inhibition or repression, which could be problematic as the cellular physiology is affected in such experiments and thus conclusions as to the stability of the transcripts might only be applicable to these stress conditions. More generally, the use of steady state levels to infer mRNA stabilities of engineered model transcripts has been used to argue for a role of codon usage in mRNA stability determination ([@bib26]; [@bib3]). These analyses are complicated by the fact that GC content alone affects the synthesis rate of mRNAs, and thus it might be necessary to measure both synthesis and decay parameters directly ([@bib42]; [@bib70]). It could also be important to consider that engineered transcripts containing high percentages of non-optimal codons, often at levels that are not found within endogenous transcripts, might be disposed of by alternate decay pathways including quality control mechanisms such as no-go decay ([@bib60]). Nevertheless, as previously reported, we also found a positive correlation between codon optimality and transcript stability ([@bib51]). However, similar positive correlations can also be identified with general translation efficiency and transcript abundance. We therefore consider it likely that these properties have undergone similar selection pressure and might have co-evolved with transcript stability to ensure optimal gene expression of particular highly abundant transcripts.

It has been previously proposed that deadenylation is the rate limiting step of mRNA decay ([@bib8]). The observation that mRNA half-lives positively correlate when measured using polyA selection compared to measurements in the absence of polyA enrichment support this model ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}). If the rate of deadenylation for each transcript was constant, one would therefore expect that the length of the polyA tail would directly determine the stability of the associated transcript. However, rather than positively correlating with half-life, we find that polyA tail length negatively correlates with transcript stability consistent with prior results ([@bib62]). Despite this inverse relationship, it is important to note the negative effects of polyA-binding protein on transcript decapping and thus the roles of deadenylation and the length of the polyA tail in controlling transcript stability are likely more nuanced than a simple rate-limiting model would imply ([@bib9]; [@bib69]). Moreover, it will be important to examine not only a snapshot of the steady state polyA tail length but to determine the kinetics of polyA tail shortening to understand if and how the rate of deadenylation contributes to overall transcript stability.

Our work also suggests that a sudden increase of decay clients leads to PB formation once a critical threshold is reached. This is consistent with previous studies showing that mRNA is required for PB formation and further implies that mRNA can be limiting for PB formation when translation is rapidly down-regulated as is the case during cellular stress. Furthermore, as mRNA decay and translation are opposing fates for an mRNA and are competing processes in the cell, it might also be the case that the cell physically compartmentalizes these processes away from one another by use of a liquid-liquid phase transition droplet such as a P-body. A remaining open question is whether PBs form because the decay machinery is overburdened and decay intermediates accumulate or whether decay substrates are delivered to PBs in order to accelerate their decay. Inducing PBs by hippuristanol treatment will be an excellent approach to dissect these possibilities as this mode of PB formation bypasses the typical stresses associated with PB formation such as nutrient starvation that might have more pervasive and confounding effects on mRNA decay itself. The role of PBs in mRNA turnover has remained unclear and controversial. Our data support the notion that mRNAs can be degraded after being delivered to a PBs. Yet, it has also been shown that mRNAs can decay co-translationally ([@bib28]). However, given that large quantities of mRNA needed to be purified to detect co-translational mRNA decay and that mRNA decay intermediates can only be visualized in PBs in the presence of mRNA stabilizing mutations or cis-stabilizing structures, it seems likely that neither of these modes of mRNA decay represent the primary pathways by which most mRNAs are destroyed ([@bib24]; [@bib48]; [@bib10]). We therefore favor a model in which most mRNAs are decayed in mRNPs that have exited translation and are composed of deadenylation, decapping and exo-nucleolytic factors existing apart from microscopically visible PBs ([@bib65]).

A revelation from this work is the overall short half-life of the transcriptome, only 4.8 min or a mean lifetime of 6.9 min. This value is three times faster than was previously measured by metabolic labeling and up to 26 times faster than what was measured by transcriptional inhibition. Despite these very short half-lives, with an estimated average translation initiation rate of 0.12 s^−1^, this implies that the average transcript can still code for about 50 polypeptides before it is destroyed ([@bib11]). This overall instability of the transcriptome argues against the need for regulated mRNA decay for the bulk of transcripts in the cell. That being said, there is a class of long lived transcripts that we and others have found to be enriched for translation factors and ribosomal protein encoding mRNAs, and there is indeed mounting evidence that these transcripts can have dramatically differing stabilities depending on the state of the cell ([@bib6]; [@bib21]). It is also important to note that our measurements were made in rapidly dividing yeast cells, and it remains to be examined whether the determinants of mRNA stability as well as the degree of regulated turnover could shift as cells are exposed to stresses or undergo differentiation programs. Our non-invasive metabolic labeling approach can be applied in such contexts to determine how decay and synthesis work together to kinetically shape dynamic gene expression programs.

Materials and methods {#s4}
=====================

Yeast Strains and Growth Conditions {#s4-1}
-----------------------------------

All strains are derivatives of W303 (KWY165) with the following exceptions: KWY7227 and KWY7246 are derivatives of BY4741 (KWY1601). All strains are listed in [Supplementary file 2](#supp2){ref-type="supplementary-material"}. *gcn2∆*, *CDC33-IAA7-3V5*, *FBA1-PP7sl*, *GFA1-PP7sl* and *PGK1-PP7sl* were generated by standard PCR based methods ([@bib33]). *RPL28(Q38K)* was generated by plating wild-type cells on 3 mg/mL cycloheximide plates, selecting for suppressors, backcrossing the suppressors at least three times and confirming the mutation by sequencing. *HIS3* was generated by PCR replacement of the *his3-11,15* allele using *HIS3* from pRS303. *leu2-3,112∆::CG-LEU2::pGPD1-OsTIR1*, *his3-11,15∆::CG-HIS3::pGPD1-OsTIR1*, *trp1-1∆::CG-TRP1::pGPD1-LexA-EBD-B112*, *his3-11,15∆::CG-HIS3::pGPD1-LexA-EBD-B112* and *SCO2::p4xLexOcyc1-3xGST-V5-24xPP7sl-tCYC1-NatNT2* were generated by transforming strains with plasmids pKW2830 (PmeI digested), pKW2874 (PmeI digested), pKW3908 (SwaI digested), pKW4073 (SwaI digested) and pKW4190 (NotI/AscI digested) respectively. Strains were grown in CSM-lowURA (7 g/L YNB, 2% dextrose, 20 mg/L adenine, 20 mg/L arginine, 20 mg/L histidine, 60 mg/L leucine, 30 mg/L lysine, 20 mg/L methionine, 50 mg/L phenylalanine, 200 mg/L threonine, 20 mg/L tryptophan, 30 mg/L tyrosine, 10 mg/L uracil) unless otherwise indicated. The following chemicals were obtained from the indicated sources: cycloheximide \[Sigma\], hippuristanol \[a generous gift of Junichi Tanaka, University of the Ryukyus\], β-estradiol \[Sigma\], sordarin \[Sigma\], 3-indoleacetic acid \[Sigma\], IP~6~ \[Sigma\], 4-thiouracil (4TU) \[Arcos\], 3-amino-1,2,4-triazole (3AT) \[Sigma\].

Plasmid Construction {#s4-2}
--------------------

All plasmids are listed in [Supplementary file 3](#supp3){ref-type="supplementary-material"} and the plasmid sequences are available as [Supplementary file 5](#supp5){ref-type="supplementary-material"}. pNH604-*pGPD1-LexA-EBD-B112* (pKW3908) was constructed by standard restriction enzyme cloning using plasmid FRP880 ([@bib45]) as a PCR template for LexA-EBD-B112 and pNH603-*pGPD1-LexA-EBD-B112* (pKW4073) was derived from this plasmid. pNH603-*pGDP1-OsTIR1* (pKW2874) and pNH605-*pGPD1-OsTIR1* (pKW2830) were constructed by standard restriction enzyme cloning using pNHK53 as a PCR template for OsTIR1 ([@bib44]). pFA6a-*IAA7-3V5-KanMx6* (pKW4325) was generated by Gibson assembly using a cDNA pool of Arabidopsis thaliana as template for IAA7. Plasmids pRS425-*p4xLexOcyc1-CDC33*(± *∆G* ± *∆CAP*)-(±*3V5*) (pKW4326, pKW4327, pKW4328, pKW4329, pKW4330, pKW4331, pKW4332 and pKW4333) were generated by a combination of Gibson assembly and site-directed mutagenesis using FRP793 ([@bib45]) as a PCR template for p4xLexOcyc1. Plasmid pRS313-*HR1_Chr2(SCO2)-p4xLexOcyc1-3xGST-V5-24xPP7sl-tCYC1-NatNT2-HR2_Chr2(SCO2)* (pKW4910) was constructed using standard restriction enzyme based cloning methods.

4TU metabolic labeling and RNA analysis {#s4-3}
---------------------------------------

Cells were grown in CSM-lowURA overnight to post-diauxic stage (OD~600~ = 1--5) and then back-diluted in CSM-lowURA at OD~600~ = 0.1. Cells were grown for at least two doublings, back-diluted to OD~600~ = 0.4 and 1 mM 4TU was added from a 1 M 4TU stock in DMSO. Cells were collected by filtration and immediately snap frozen in liquid nitrogen. Cell pellets were resuspended in 400 μL ice-cold TES buffer (10 mM TrisHCl pH7.5, 10 mM EDTA, 0.5% SDS) containing 5 ng 4TU-*srp1α*(Hs) -polyA spike RNA and 5 ng *rcc1*(Xl)-polyA spike RNA. 400 μL acid-saturated phenol was added and samples were continuously vortexed for 1 hr at 65°C. The aqueous phase was then subjected to an additional phenol extraction followed by chloroform extraction and then isopropanol precipitated. Total RNA was pelleted, resuspended and 14 μg was biotinylated with MTSEA-biotin \[Biotium\] as previously described ([@bib16]). 10 μg of biotinylated total RNA was then subjected to oligo-dT bead \[Life technologies\] selection or 500 ng total RNA was used as input for the streptavidin bead selection depending on the experiment. 25 μL MyOne streptavidin C1 Dynabeads \[Life technologies\] were washed with 25 μL each of 0.1 M NaOH (2x), 0.1 M NaCl (1x) and buffer3 (10 mM TrisHCl pH7.4, 10 mM EDTA, 1 M NaCl) (2x). The beads were then resuspended in 25 μL buffer3 and 2.5 μL 50x Denhardt's reagent was added. Beads were then incubated with gentle agitation for 20 min, washed with 75 μL buffer3 (4x) and resuspended in 25 μL buffer3 with 2 μL 5 M NaCl added. Biotinylated RNAs were added to the blocked streptavidin beads and incubated with gentle agitation for 15 min. The flowthrough was collected and the beads were washed with 75 μL each buffer3 prewarmed to 65°C (1x), buffer4 (10 mM TrisHCl pH7.4, 1 mM EDTA, 1%SDS) (1x) and 10%buffer3 (2x). The washes were pooled with the flowthrough and 25 μL 5 M NaCl and 15 μg linear acrylamide \[Ambion\] were added prior to isopropanol precipitation. Biotinylated RNAs were eluted from the streptavidin beads first by a 5 min incubation with gentle agitation in 5% β-mercaptoethanol and a subsequent 10 min incubation at 65°C in 5% β-mercaptoethanol. Eluates were pooled and 7 μL 5 M NaCl and 15 μg linear acrylamide were added prior to isopropanol precipitation. RNAs were DNaseI \[NEB\] treated prior to downstream analysis. 4TU-*srp1α*(Hs)-polyA and *rcc1*(Xl)-polyA spike RNAs were generated as previously described using plasmids pKW1644 and pKW1643 respectively ([@bib41]).

RT-qPCR quantification of RNA abundance {#s4-4}
---------------------------------------

2--50 ng of mRNA (depending on sample) was used for reverse transcription using Superscript II \[Life technologies\] with random hexamer primers. cDNA was quantified on a StepOnePlus Real-Time PCR system using a SYBR green PCR mix \[ThermoFisher\] with gene specific primers ([Supplementary file 4](#supp4){ref-type="supplementary-material"}).

High-throughput sequencing and RNAseq quantification {#s4-5}
----------------------------------------------------

50--100 ng mRNA was used as input material to generate strand-specific sequencing libraries using the NEXTflex Rapid Directional Illumina RNA-Seq Library Prep Kit \[BioO\] according to the manufacturer's instructions. The libraries were sequenced on an Illumina HiSeq 4000 sequencer by the QB3 Vincent J. Coates Genomics Sequencing Laboratory. Reads were mapped, aligned and quantified using the Tuxedo tools ([@bib66]).

Immunoblot analysis {#s4-6}
-------------------

For immunoblot analysis of Cdc33-3V5 and Cdc33-IAA7-3V5, cell were pelleted and resuspended in 5% ice-cold trichloroacetic acid for a minimum of 10 min. The acid was washed away with acetone and cell pellets were air-dried overnight. The pellet was resuspended in 100 μL lysis buffer (50 mM Tris-HCl pH 7.5, 1 mM EDTA, 2.75 mM DTT) and pulverized with glass beads in a beadmill \[BioSpec\] for 5 min. Sample buffer was added and the lysates were boiled for 5 min. V5 tagged proteins were detected with a mouse anti-V5 antibody \[Life technologies, RRID: [AB_2556564](https://scicrunch.org/resolver/AB_2556564)\] at a 1:2000 dilution. Hexokinase (Hxk1) was detected using a rabbit anti-hexokinase antibody \[H2035, Stratech, RRID: [AB_2629457](https://scicrunch.org/resolver/AB_2629457)\] at a 1:10,000 dilution. IRdye 680RD goat-anti-rabbit \[LI-COR Biosciences, RRID: [AB_10956166](https://scicrunch.org/resolver/AB_10956166)\] and IRdye 800 donkey-anti-mouse \[LI-COR Biosciences, RRID: [AB_621847](https://scicrunch.org/resolver/AB_621847)\] were used as secondary antibodies.

Data processing and half-life determination {#s4-7}
-------------------------------------------

RNA measurements were first normalized by the abundance of the spike RNA (*rcc1*(Xl) for decay measurements and *srp1α*(Hs) for synthesis measurements) and then normalized to the t = 0 value. These data were then fitted to the following decay model:$$RNA\left( t \right) = eff*2^{- t/T_{h}} + \left( 1 - eff \right)$$

Where $eff$ is a bulk efficiency term that accounts for the efficiency of 4TU labeling, biotin conjugation and separation of biotinylated RNAs from unbiotinylated RNAs and $T_{h}$ is the half-life. A script was written in R to perform filtering, normalization and fitting of the decay data (https://github.com/LeonYenLeeChan/RNAdecay; copy archived at <https://github.com/elifesciences-publications/RNAdecay>). For synthesis rate determination, data were fit to:$$RNA\left( t \right) = k_{s}*t + offset$$

Where $k_{s}$is the synthesis rate and the $offset$is the y-intercept. Please see appendix 1 for more details.

Growth determination {#s4-8}
--------------------

Cells were grown to mid-log phase, back diluted to OD 0.1--0.3 and growth at 30°C was monitored either manually by measuring absorbance at 600 nm or in a Tecan Infinite M1000 plate reader \[Tecan\].

Wide-field fluorescence microscopy {#s4-9}
----------------------------------

Cells for imaging experiments were grown to exponential phase in CSM + 2% dextrose. Cells were then transferred onto Concanavalin A-treated 96-well glass bottom Corning plates (Corning, Corning, NY). For experiments described in [Figure 4A--C](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1B--C](#fig1s2){ref-type="fig"} cells were visualized at room temperature using the DeltaVision Elite Imaging System with softWoRx imaging software (GE Life Sciences, Marlborough, MA). The system was based on an Olympus 1 × 71 inverted microscope (Olympus, Japan), and cells were observed using a UPlanSApo 100 × 1.4 NA oil immersion objective. Single plane images were acquired using a DV Elite CMOS camera. For experiments described in [Figure 4D--F](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1D](#fig1s2){ref-type="fig"}, cells were visualized at room temperature using an inverted epi-fluorescence microscope (Nikon Ti) equipped with a Spectra X LED light source and a Hamamatsu Flash 4.0 sCMOS camera using a 100x Plan-Apo objective NA 1.4 and the NIS Elements software. Quantification of co-localization was performed on all planes of a 3D stack using the Colocalization Threshold tool in FIJI. Image processing for PB counting was performed using Diatrack 3.5 particle tracking software.

Spinning disk confocal microscopy {#s4-10}
---------------------------------

Samples were grown in CMS + 2% dextrose to exponential phase and imaged using an Andor/Nikon Yokogawa spinning disk confocal microscope (Belfast, United Kingdom) with Metamorph Microscopy Automation and Image Analysis software (Molecular Devices, Sunnyvale, CA). The system was based on a NikonTE2000 inverted microscope and cells were observed using a PlanApo100 ×1.4 NA oil immersion objective and single plane images were captured using a Clara Interline CCD camera (Andor).
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Extended technical appendix detailing the development and refinement of the 4TU-chase labeling experiment {#s7}
=========================================================================================================

To avoid the multiple problems associated with measuring mRNA stability using global transcriptional inhibition, we sought to employ metabolic labeling methods that would allow us to measure these kinetic parameters in a minimally invasive manner. We developed a working method and used this to collect one of the first profiles of mRNA stability in yeast cells ([@bib41]). Briefly, we grew cells to early exponential phase, labeled them with 0.2 mM 4TU for 2 hr and then transferred the cells to fresh media containing 19.6 mM (2.2 mg/mL) uracil. We collected cells from a timecourse during the chase phase and extracted total cellular RNA. We biotinylated these RNAs with HPDP-biotin, selected for the poly-adenylated fraction using oligo-dT beads and finally separated labeled mRNAs (here the 'old-mRNA' pool) from unlabeled mRNAs ('newly-synthesized' pool). Based on follow-up work as well as the lack of agreement between our dataset and other metabolic-labeling based mRNA stability profiles, we sought to reexamine and improve our first-generation method.

To begin to test our method, we made use of the osmotic shock responsive gene, *STL1*. Upon osmotic shock, *STL1* mRNA is rapidly and transiently induced ([Appendix1---figures 1A and B](#app1fig1){ref-type="fig"}) ([@bib1]). We performed our 4TU pulse-chase labeling and then subjected cells to an osmotic shock with the addition of 0.4M NaCl. If the pulse-chase labeling were performing optimally, we would expect that all *STL1* mRNAs would contain only unmodified uracil. Rather, we found that a sizable fraction (about 40%) of *STL1* transcripts were eluted from the streptavidin beads ([Appendix1----figure 2](#app1fig2){ref-type="fig"}). This bleed through of a newly-made transcript into the labeled 'old-transcript' pool could be a reflection of a number of possible technical problems. First, this could indicate that the chase phase is inefficient in preventing newly made transcripts from being labeled with 4TU. Second, this could indicate that the conjugation of biotin to the thiolated mRNA could be inefficient. Third, this bleed through could also be a symptom of carryover during the separation of thiolated mRNA from unlabeled mRNA. And fourth, it could be the case that our mathematical model requires modification to account for bleed through which cannot be addressed by experimental optimization.

![Kinetics of *STL1* mRNA induction.\
(**A**) Wild-type cells (KWY165) were grown to exponential phase, subjected to a 0.4 M NaCl salt shock and samples were collected at the indicated times for northern blot analysis. (**B**) Quantification of data in (**A**). *STL1* mRNA levels were corrected to background and also to rRNA levels.](elife-32536-app1-fig1){#app1fig1}

![Chase inefficiency as revealed by *STL1* induction.\
Wild-type cells (KWY165) were grown to OD~600~ = 0.2, labeled with 0.2 mM 4TU for 2 hr and then washed out of the labeling media. Half of the cells were returned to the same media and the other half were resuspended in chase media containing 19.6 mM uracil. Both cultures were immediately subjected to 0.4 M NaCl salt shock and samples were collected 10 min after the salt shock. Thio-labeled mRNAs were purified and abundance of *STL1* thio-mRNA was determined by qPCR, normalized to a thio-labeled spike (*srp1α (Hs)*) and then normalized to the levels of *STL1* in pre-salt shocked cells (t = 0).](elife-32536-app1-fig2){#app1fig2}

The non-linear nature of detection based on affinity capture is inherent to the 4TU method and is a possible contributor to the bleed through problem. Put another way, in theory, an mRNA containing one thio-uracil could be treated the same as an mRNA containing 100 thio-uracils in the context of affinity purification. This is not an issue if the pulse-chase is performing optimally but even a small inefficiency in the chase, specifically new transcripts continuing to incorporate a low level of 4TU, would result in bleed through. We tested this possibility by again making use of the *STL1* system and varied the time of salt-shock and observed the degree to which newly made *STL1* mRNA partitioned between the bead-captured eluate and flowthrough fractions. We found that immediately upon uracil chase, salt shock led to a majority of newly made *STL1* transcripts being retained on the streptavidin beads. As we increased the lag time between uracil chase and salt-shock, we found that an increasing fraction of *STL1* mRNAs partitioned into the flowthrough ([Appendix1---figures 3A and B](#app1fig3){ref-type="fig"}). The trend of increasing chase efficiency as time after chase was increased gave us a clear indication that inefficient chase was indeed a problem. We sought to correct this problem by switching from the existing 4TU-pulse/uracil-chase to a 4TU-chase labeling scheme where the non-linear nature of affinity capture-based detection is an advantage rather than a disadvantage. We grew cells to mid-exponential phase (OD~600~ = 0.4) and then added 0.2 mM 4TU to the culture. We again varied the time of salt-shock post 4TU chase and observed how the newly synthesized *STL1* transcript partitioned in the bead capture. We observe that even with no lag phase between 4TU chase and salt-shock, most of the newly synthesized *STL1* mRNA was effectively captured by the streptavidin beads. As the lag time was increased, a greater fraction of newly made *STL1* transcript was captured by the streptavidin beads ([Appendix1---figures 3C and D](#app1fig3){ref-type="fig"}).

![Analysis of chase efficiencies as a function of lag time and labeling scheme.\
(**A**) 4TU-pulse/uracil-chase labeling scheme and experimental setup for (**B**). (**B**) Wild-type cells (KWY165) were grown to exponential phase, the experiment outlined in (**A**) was performed and levels of *STL1* mRNA were determined by northern blot. (**C**) 4TU-chase labeling scheme and experimental setup for (**D**). (**D**) Wild-type cells (KWY165) were grown to exponential phase, the experiment outlined in (**C**) was performed and levels of *STL1* mRNA were determined by northern blot.](elife-32536-app1-fig3){#app1fig3}

In addition to the switch in labeling scheme, we also tested the possibility that higher concentrations of 4TU in the chase could lead to improved new-transcript labeling. We titrated 4TU concentrations and found that the maximum tolerated dose of 4TU was 1 mM in our CSM-lowURA media ([Appendix1---figure 4](#app1fig4){ref-type="fig"}). Higher concentrations inhibited cell growth and would be self-defeating with respect to measuring mRNA dynamics in a minimally-perturbed system. We measured the stability of the *ACT1* transcript using a 0.2 mM 4TU-chase or a 1 mM 4TU-chase. Use of the higher 4TU concentration enabled a more efficient chase as indicated by the lower levels of *ACT1* transcript in the flowthrough fractions especially later in the timecourse ([Appendix1---figure 5](#app1fig5){ref-type="fig"}).

![Effects of 4TU on cell growth.\
Wild-type cells (KWY165) were grown to exponential phase, treated with the indicated concentration of 4TU and growth was monitored by absorbance at 600 nm.](elife-32536-app1-fig4){#app1fig4}

![Increasing the 4TU concentration during the chase improves the subtraction of newly synthesized mRNAs.\
Wild-type cells (KWY165) were subjected to the 4TU-chase protocol with either 0.2 mM 4TU in the chase (orange) or 1 mM 4TU (blue) and the unlabeled *ACT1* mRNA levels were quantified.](elife-32536-app1-fig5){#app1fig5}

We also examined if introducing a lag period between 4TU-chase and beginning the collection of the mRNA stability timecourse improved the efficiency of new transcript labeling. We measured the stability of the *ACT1* mRNA with a range of lag times. We found that even a brief lag period (2 min) improved the efficiency and consistency of the method ([Appendix1---figure 6](#app1fig6){ref-type="fig"}). Increasing lag times beyond 2 min did not improve the quality of the data. Moreover, increasing lag times is a balancing act; some lag is beneficial for robust labeling but an overly long lag period fails to capture the dynamics of the most rapidly decayed mRNAs. Thus we opted for the 2 min lag time where we still observed a beneficial effect.

![Introducing a brief lag period between the 4TU-chase and starting the decay timecourse improves the quality of the decay data.\
Wild-type cells (KWY165) were subjected to the 4TU-chase protocol. A variable amount of time was allowed to elapse between the 4TU-chase and collection of the t = 0 sample and the unlabeled *ACT1* mRNA levels were quantified.](elife-32536-app1-fig6){#app1fig6}

Having optimized the labeling conditions, we next turned our attention to potential issues with carryover during the streptavidin bead-based RNA separation. We examined how unlabeled transcripts partitioned between the bead-bound and flowthrough fractions. We found that indeed unlabeled RNAs were being retained on the beads and moreover, different RNAs were retained to different degrees (compare [Appendix1-figure 3D](#app1fig3){ref-type="fig"} lanes 1--3 for *STL1* and [Appendix 1---figure 7](#app1fig7){ref-type="fig"} lanes 1--3 for *rcc1 (Xl)*). This is especially problematic as it implies that in addition to a global distortion of mRNA stability, bead carryover can produce transcript specific artifacts as well thus complicating even relative comparisons of mRNA half-lives. We reasoned that improvements to both bead blocking as well as bead washing could mitigate this carryover problem. We tested a variety of blocking agents such as single-stranded salmon sperm DNA, polyA RNA, heparin and Denhardt's reagent in addition to bacterial tRNAs as was used in our first-generation method. We found that bead-blocking with Denhardt's reagent resulted in a marked improvement in unlabeled RNA carryover. Moreover, we found that this bead-blocking method did not interfere with the capture of an in vitro generated thio-labeled *srp1α (Hs)* RNA ([Appendix1-figure 7](#app1fig7){ref-type="fig"}). We also examined how unlabeled RNAs were washed off the beads in the wash steps following streptavidin bead capture. We found that most of the unlabeled RNA was contained in the flowthrough fraction. A fraction of remaining RNA that stuck to the beads was released with a high-salt 65C wash step but further washes with this buffer were ineffective in releasing additional non-specifically bound RNAs. We took advantage of the fact that the biotin-streptavidin interaction is resistant to SDS concentrations as high as 3%. With the addition of a single 1% SDS wash, we were able to release the majority of the remaining unlabeled RNA from the beads ([Appendix1-figure 8](#app1fig8){ref-type="fig"}). Additional washes with this buffer did not release a significant amount of unlabeled RNAs. Again, we found that this more stringent wash protocol did not interfere with the ability of the streptavidin beads to properly capture labeled RNAs.

![Analysis of streptavidin bead blocking efficiency.\
Wild-type cells (KWY165) were labeled with 1 mM 4TU for 2 hr. 5 ng of in vitro transcribed *rcc1 (Xl)* mRNA spike and 5 ng of in vitro transcribed 4TU-labeled *srp1α (Hs)* mRNA spike were added to 10 μg of extracted total RNA and the RNA mix was biotinylated. mRNAs were enriched for using oligo-dT beads and the mRNAs were then subjected to streptavidin bead selection. Streptavidin beads were prepared using the indicated blocking agents and the total (TOT), eluate (ELU) and flowthrough plus washes (FT + W) fractions were analyzed by northern blot.](elife-32536-app1-fig7){#app1fig7}

![Analysis of unlabeled mRNA release during streptavidin bead purification.\
RNA mixtures were prepared as in [Appendix1---figure 7](#app1fig10){ref-type="fig"} and total (TOT), eluate (ELU) flowthrough (FT) and wash (WASH1-WASH9) samples were analyzed by northern blot.](elife-32536-app1-fig8){#app1fig8}

Recently, an improved biotin crosslinker, MTSEA-biotin, was developed and we tested if MTSEA-biotin performed better in our second-generation metabolic labeling method compared to the standard HPDP-biotin ([@bib16]). We collected a decay timecourse and processed the RNA in parallel only differing the biotin-crosslinker and analyzed the resulting decay curves. We found that the MTSEA-biotin resulted in better labeling evidenced by the reduced unlabeled mRNA levels we observed later in the timecourse ([Appendix1---figures 9A and B](#app1fig9){ref-type="fig"}).

![Comparison of HPDP-biotin with MTSEA-biotin in the efficiency of subtracting newly synthesized mRNAs during the chase phase.\
Wild-type cells (KWY165) were subjected to the 4TU-chase protocol and RNAs were biotinylated with either HPDP-biotin (orange) or MTSEA-biotin (blue). Levels of unlabeled *CIS3* and *RPL25* mRNAs were determined.](elife-32536-app1-fig9){#app1fig9}

Lastly, we revisited our computational model and examined the effects of what remaining inefficiencies in labeling and capture might have on simulated decay curves. We observed that as the efficiency of labeling and capture decreases, the curves become shallower and plateau at a non-zero steady state value ([Appendix1---figure 10A and C](#app1fig10){ref-type="fig"}). Note that for a long lived transcript, fitting these data to a single exponential decay model can result in dramatically longer half-lives with little loss of goodness of fit ([Appendix1---figure 10B](#app1fig10){ref-type="fig"}). In the case of very unstable transcripts, the single exponential decay model completely fails for even modest levels of inefficiency ([Appendix1---figure 10D](#app1fig10){ref-type="fig"}). To properly model these data, we introduced an efficiency of labeling and capture parameter to the standard decay model:

![Simulation of the effects of non-ideal efficiencies in labeling and streptavidin bead separation on decay kinetics.\
(**A**) Decay data for an mRNA with a 10 min half-life were simulated with variable degrees of labeling and purification efficiencies. (**B**) The simulated data in (**A**) were fit to a single exponential decay model (RNA(t)=RNA(0)\*2 ^t/hl^ where hl is the half-life) and the half-lives and goodness of fits (R^2^) were determined. (**C**) Decay data for an mRNA with a 0.4 min half-life were simulated with variable degrees of labeling and purification efficiencies. (**D**) The simulated data in (**C**) were fit to a single exponential decay model (RNA(t)=RNA(0)\*2 ^t/hl^ where hl is the half-life) and the half-lives and goodness of fits (R^2^) were determined.](elife-32536-fig10){#app1fig10}

$$RNA\left( t \right) = eff*2^{- t/T_{h}} + \left( 1 - eff \right)$$where *T~h~* is the half-life and *eff* is a bulk efficiency of labeling and thio-RNA capture. Note that in the limiting case where the efficiency approaches 1, the equation reduces to the single exponential decay model. We used this two parameter model for all of our half-life determinations. Moreover, we did not use a global efficiency parameter but rather fit each transcript to its own efficiency as there are transcript specific contributions to this bulk parameter such as bead-stickiness and uracil content.

We made one final modification to the 4TU method with regard to spike-in control RNAs that normalize for differences in the various RNA recovery and bead binding steps of the 4TU protocol. In our first generation protocol, we spiked in control RNAs relative to a constant amount of total RNA which is comprised mostly of rRNA. We then accounted for the mRNA 'decay by dilution' due to cell growth and division by correcting for the growth rate. This method introduces the errors of growth rate determination as well as RNA quantification into the protocol. We reasoned that in theory, adding our spike-in controls relative to a constant **culture volume**, would eliminate the need to correct for 'decay by dilution.' The only caveat to this approach is the assumption that the efficiency of cell lysis is relatively constant. We set out to test this assumption. We found that for lysing six identical cell pellets that there was a 3% standard deviation in RNA recovery ([Appendix1---figure 11](#app1fig11){ref-type="fig"}). We also tested the linearity of recovery of RNA from increasing sizes of cell pellets and found that that the recovery of RNA was robustly linear to input cell material over the range of our experiments ([Appendix1---figure 12](#app1fig12){ref-type="fig"}). We concluded that spiking relative to culture volume is an improvement on the first-generation metabolic labeling protocol.

![Reproducibility of cell lysis during RNA extraction.\
Wild-type cells (KWY165) were grown to exponential phase and six technical replicate cell pellets of 5 OD~600~ units were collected. 10 ng of in vitro transcribed *rcc1 (Xl)* mRNA spike was added to each sample and the cells were subjected to the RNA extraction protocol. Levels of *ACT1* and the spike mRNAs were determined and the ratio of *ACT1*:spike normalized to replicate one is plotted.](elife-32536-app1-fig11){#app1fig11}

![Reproducibility of cell lysis during RNA extraction.\
Wild-type cells (KWY165) were grown to exponential phase and two technical replicate cell pellets of varying OD~600~ units were collected. 10 ng of in vitro transcribed *rcc1 (Xl)* mRNA spike was added to each sample and the cells were subjected to the RNA extraction protocol. Levels of *ACT1* and the spike mRNAs were determined and the ratio of *ACT1*:spike is plotted. The shaded area indicates the OD~600~ range in which the 4TU-chase experiments are performed.](elife-32536-app1-fig12){#app1fig12}

In total, we re-examined each step of our 4TU protocol and made improvements where possible. We then introduced a modified mathematical model to account for the remaining inefficiencies in the protocol that we could not experimentally correct. This has resulted in an improved second generation 4TU protocol that is accurate and reproducible.

Experimental Procedures {#s8}
=======================

Northern blot analysis {#s8-1}
----------------------

Northern blot experiments were performed as previously described ([@bib10]). Oligonucleotide probes are as follows:

*STL1* GATTTTGGGACCTGCCTCTGGAGAACAAACTTGACAGTG

*rcc1 (Xl)* GAAAGACCAAAGCCATATACATGGCCTTCTTGGGACACCGC

*srp1*α (Hs) GGGCTGTTTTTCTCTGGAAAGTAGTTTCCTGGCAGCTTGAG
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Thank you for submitting your article \"Non-invasive measurement of mRNA decay reveals translation initiation as the major determinant of mRNA stability\" for consideration by *eLife*. Your article has been reviewed by James Manley (Senior Editor), a Reviewing Editor, Alan Hinnebusch, and three reviewers three peer reviewers, The following individual involved in review of your submission has agreed to reveal his identity: Roy Parker (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. The essential revisions may take more than the usual two months we suggest for return of a revised manuscript but given the enthusiasm for this work, we are willing to extend that limit if it proves necessary. It would help to have your response to the essential revisions and an estimate of the time it will take to complete these tasks.

Summary:

Chan et al. present an improved method for measuring the kinetics of mRNA synthesis and degradation that minimizes perturbation of cellular state and that accounts for various potential sources of non-biological variation. They apply this method to measure the half-lives of each type of mRNA in yeast and produce results that are strikingly different from those produced by earlier approaches. In particular, they find that average half-lives are substantially shorter than previously measured. Seeking to explain gene-by-gene variation in mRNA stability, the authors identify rates of translation initiation and optimal codon content as having similarly strong positive correlations with half-life. To distinguish between the more historical model in which the presence of ribosomes protects messages from decay machinery and a newer model in which slow elongation (e.g. of non-optimal codons) serves as a general trigger of decay, the authors measure mRNA stability after applying a variety of chemical and genetic methods of interfering with elongation or with initiation. They find that slow elongation stabilizes mRNA, while slow initiation destabilizes mRNA, favoring a model in which competition for access to the cap, rather than sensing of slow moving ribosomes, serves as the primary gatekeeper for decay pathways.

Essential revisions:

The most important issue to be addressed is whether your use of poly(A) selection has led you to measure the half-lives of only a fraction of mRNAs with poly(A) tails long enough for oligo-dT selection or, in the limit case, to measure rates of deadenylation only. It is necessary that you alter your technique to avoid poly(A) selection by using ribo0 depletion as an alternative approach and determine whether your major conclusions about mRNA half-lives and the relatively greater importance of translation initiation versus elongation rates in determining half-lives still hold.

Second, the reviewers were not convinced of the statistical significance of differences in half-lives of specific mRNAs being claimed in the Results, requiring more thorough documentation of replicates with the appropriate statistical analyses.

Third, because your most significant results at odds with the previous model positing that mRNA decay is triggered by stalled ribosomes containing an empty A-site came from analyzing turnover rates in gcn2 cells treated with 3AT, this approach should be conducted genome-wide to analyze the correlation (or lack thereof) between ribosome stalling at His codons and mRNA half-life.

Fourth, for the experiments using hippuristanol or dominant-negative eIF4E/degron depletion of eIF4E to inhibit translation initiation, it should be verified that the translation initiation rate was reduced for the specific mRNAs whose half-lives are being measured.

Fifth, additional revisions of the text are required to reconcile your model with the results of previously published experiments on reporter mRNAs that provided strong evidence that codon optimality is a strong determinant of mRNA half-life, which would suggest that this mRNA feature has not merely co-evolved with translation initiation efficiency in the manner you suggest.

Sixth, it seems necessary to address the alternative interpretation of your experiments on P-bodies raised by reviewer \#1.

Reviewer \#1:

This paper describes an improved, non-invasive method for genome-wide measurements of mRNA half-lives in growing yeast cells. The results suggest that mRNA half-lives are between 3-fold and 26-fold shorter than determined previously by other approaches relying on metabolic labeling or inhibition of transcription, respectively. By examining the effects of inhibiting translation elongation or initiation on mRNA half-lives in various ways, that conclude that the rate of translation initiation is a more important determinant of mRNA half-life than is the rate of elongation, at odds with recent reports from the Coller and Green labs indicating that codon optimality is the principle determinant of mRNA stability of native mRNAs in budding yeast. They provide evidence that stalling ribosomes during elongation with the inhibitors cycloheximide or sordorin, or by starving for the amino acid histidine, tends to decrease rather than increase rates of mRNA turnover, presumably by having stalled ribosomes protect the mRNA from nucleolytic digestion, rather than inducing turnover via Dhh1 recognition of stalled ribosomes as recently concluded by Coller and Green. By contrast, an inhibitor of eIF4A or mutants that reduce eIF4F function and presumably produce a global decrease in the initiation rate lead to increased mRNA turnover. Thus, they propose that the rate of initiation is the key determinant of mRNA stability, with a reduction in initiation either exposing the mRNA cap to the decapping machinery or decreasing ribosome densities on coding regions. Based on the fact that inhibiting eIF4A with hippuristanol (HIP) induces Dhh1-dependent P-bodies, and that the abundance of a stem-loop reporter mRNA in P bodies decayed over time, they propose that inhibiting initiation sends mRNAs to P bodies and that this is, or can be, the site of their decay.

\- The differences in half-life claimed for ACT1 and CIS3 mRNAs in response to CHX treatment in Figure 3---figure supplement 1 and Figure 3B are unconvincing, and they have provided no half-life values for these experiments. The claim that RPS2, RPL25, CIS3 and OSW5 mRNAs exhibit slower turnover on 3AT treatment are similarly unconvincing.

\- The most significant results presented here that are at odds with the proposal of Coller/Green, that decay is triggered by stalled ribosomes containing an empty A-site, came from analyzing turnover rates in gcn2 cells treated with 3AT to induce histidine starvation and attendant stalling by elongating ribosomes at histidine codons genome-wide. The experiments using CHX or sordorin are not relevant because these drugs do not stall ribosomes with an empty A site. As such, in order to justify their claim that inhibiting elongation in this manner slows down rather than accelerates mRNA decay on a genome-wide level, it is necessary to obtain mRNA turnover data for the entire transcriptome using their technique in 3AT-treated gcn2 cells, rather than examining only a dozen mRNAs by RT-qPCR. In addition, because the previous ribosome profiling experiments using 3AT carried out in the Green lab, which they cite for the effect of 3AT in stalling ribosomes, employed a GCN2+ strain, it is necessary that they confirm that treating a gcn2 mutant with 3AT will cause a similar (or even greater) degree of pauses at histidine codons by elongating ribosomes, and to demonstrate a widespread lack of correlation between pausing at histidine codons measured by ribosome profiling and mRNA half-lives measured by their technique in 3AT-treated cells.

\- The authors have used treatment with hippuristanol (HIP), or overexpression of a dominant-negative eIF4E variant lacking cap-binding activity together with degron depletion of eIF4E, as alternative means to inhibit global translation initiation rates. However, they have relied only on cell growth assays to document these effects. It is necessary to show by a more direct assay that translation initiation is impaired for the specific mRNAs whose half-lives are being measured (ACT1, CIS3, and RPL25). The best approach would be to show that the average number of ribosomes per mRNA is reduced on these mRNAs by the treatments shown in Figure 3H-I by probing for these mRNAs across fractionated polysomes; the effects on abundance and average size of bulk polysomes will be obtained in parallel. Alternatively, they could show that the amounts of these mRNAs associated with eIF4G (RNA-IP) are reduced by the two treatments. Treatment with sordarin or CHX would be a key negative control for either approach.

\- In Figure 3---figure supplement 2C-D, there are unexplained increases in synthesis of RPL25 in response to CHX and sordorin that require comment.

\- The interpretation of the results in Figure 4E, that the reporter mRNA is being degraded in P-bodies, seems to overlook the possibility that the reporter mRNA exchanges rapidly between P-bodies and other compartments, in which case it could be degraded elsewhere, e.g. on polysomes, and its abundance in P-bodies would merely indicate the overall cellular level of the transcript. Is there a way to eliminate this alternative?

\- The validity of this method for measuring mRNA half-lives depends on highly efficient incorporation of 4-thioU into all newly synthesized mRNAs, and also highly efficient separation of these mRNAs from the un-labeled mRNAs pre-existing before the 4-thioU pulse, as it is the decay of the later over time that is quantified to determine half-lives. Extracting decay rates from the data requires a theoretical model for the decay, which includes an \"efficiency parameter\". It is difficult to assess the validity of this model, and hence, the mRNA half-lives determined using it. This is worrisome because their measured half-lives are 3-fold shorter than those measured by other labs using non-invasive metabolic labeling, and there is no attention given to resolving these discrepancies. The authors have provided and extended technical supplement on the refinement of their technique, but it seems important to provide justification for the validity of the modeling and method for extracting turnover times in the main text of the paper.

Reviewer \#2:

Chan et al. present an improved method for measuring the kinetics of mRNA synthesis and degradation that minimizes perturbation of cellular state and that accounts for various potential sources of non-biological variation. They apply this method to measure the half-lives of each type of mRNA in yeast and produce results that are strikingly different from those produced by earlier approaches. In particular, they find that average half-lives are substantially shorter than previously measured. Seeking to explain gene-by-gene variation in mRNA stability, the authors identify rates of translation initiation and optimal codon content as having similarly strong positive correlations with half-life. To distinguish between the more historical model in which the presence of ribosomes protects messages from decay machinery and a newer model in which slow elongation (e.g. of non-optimal codons) serves as a general trigger of decay, the authors measure mRNA stability after applying a variety of chemical and genetic methods of interfering with elongation or with initiation. They find that slow elongation stabilizes mRNA, while slow initiation destabilizes mRNA, favoring a model in which competition for access to the cap, rather than sensing of slow moving ribosomes, serves as the primary gatekeeper for decay pathways.

This is important work that has been carefully designed and executed. The unexpectedly strong connection between codon optimality and mRNA decay has emerged as a major area of research over the last three years, and intense efforts are underway to understand the molecular mechanisms that underpin this connection. By calling into question one of the central assumptions of this new sub-field (namely, that slowing down elongation should destabilize mRNA), Chan et al., trigger a messy but necessary rethinking of our understanding of these phenomenon.

1\) Presnyak et al., 2015 argues that enriching for mRNA by polyA pulldown produces artificially depressed estimates of half-lives due to the existence of stable deadenylated messages. Why did the authors use polyA pulldown in their protocol? Could this effect contribute to the shorter half-lives they observe? (It is unclear exactly which datasets from this paper are the two Coller datasets in Figure 1---figure supplement 1G.)

2\) The authors argue that, given their results, the observed positive correlation between optimal codon content and half life is likely to be due to co-evolution rather than direct causal connection. Several papers (PMIDs: 25768907, 27436874, 27641505, and others), however, have presented compelling evidence for a direct causal connection by showing that systematically deoptimizing the codon content of a reporter construct systematically reduces its stability. To some extent, the authors\' results contradict the standard interpretation of these published experiments. The paper would be strengthened if the authors engaged with this contradiction head-on by more thoroughly discussing exactly which ideas in this field are and are not consistent with their new data.

Reviewer \#3:

This manuscript addresses the relationship between steps in translation and mRNA degradation in yeast. The manuscript addresses an important and timely issue in the field: Is decay rate coupled to stalled ribosomes, or to poor translation initiation? This has become an issue because of two competing lines of work. First, previous work using reporter mRNAs showed that translation initiation was in competition with decay (both deadenylation and decapping). However, more recent work, using both genome wide analyses and reporter mRNAs has argued that inefficient translation elongation (as defined by non-optimal codons) is the predominant driver of mRNA decay rates. Thus, resolving this issue will be important for understanding mRNA decay control.

The strength of this manuscript is that is uses genome wide analyses of mRNA decay rates both under normal conditions, and with perturbations that affect ribosome elongation rates or translation initiation rates. The main conclusion from the work is that slow ribosome movement actually stabilizes mRNAs, while decreasing translation initiation increases mRNA degradation. This is a useful contribution and worthy of consideration for publication in *eLife*, although there are substantive issues that should be addressed before publication.

1\) The biggest issue with the manuscript is that the procedure for mRNA decay rates involves an oligo(dT) selection step. Since many mRNAs in yeast exist at steady state as oligoadenylated or deadenylated mRNAs (see Herrick et al., 1990 MCB), this only selects for a substep of mRNAs (typically with A tails longer than 30). Thus, the approach is really only measuring the deadenylation rate of mRNAs and not overall decay. This is presumably why their decay rates are faster than what has been described previously using methods that do not rely on selection of A+ mRNA species. The best approach for the authors here would be to repeat the experiments using ribo0 RNA, which would allow them to access the full mRNA decay pathway. Alternatively, they could re-write the manuscript as simply studying deadenylation, but this would diminish the impact of the work.

2\) In Figure 3B, the differences in decay curves are slight and would need to be supported by error bars to convince the reader these are meaningful. In fact, the data might be more convincing if decay rate was measured with ribo0 RNA since previous work (Beelman and Parker, 1995 and others) had shown cycloheximide primarily inhibits decapping with little effect on deadenylation rate.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Non-invasive measurement of mRNA decay reveals translation initiation as the major determinant of mRNA stability\" for further consideration at *eLife*. Your revised article has been favorably evaluated by James Manley (Senior Editor), a Reviewing Editor, Alan Hinnebusch, and three reviewers.

All three reviewers agreed that the paper has been significantly improved by the new experiments that were carried out, as well as the revisions of text; and your efforts to address all of the major criticisms of the first version were greatly appreciated. In particular, the new genome-wide data obtained from analyzing total RNA generally supports the conclusions reached from poly(A) selection, which resolves the most important criticism of the original version of the paper.

There are, however, some remaining issues that require your attention, raised by reviewer \#1, including the lack of statistical significance of small differences in mRNA half-lives for certain mRNAs, and the apparent lack of any replicates for the new half-life measurements conducted with total RNA. There is also an objection to your interpretation of the new results presented to establish a shift to smaller polysomes of mRNAs in response to down-regulating eIF4E/4G; and a concern that these experiments might have been conducted only once without replication. It is felt that these shortcomings detract from the overall scientific quality of the work and do not satisfy the journal\'s rigorous standards for replicate measurements and statistical analyses of data. Finally, you have been asked to consider whether the magnitude of the observed effects of reducing initiation or elongation in decreasing or increasing mRNA stabilities, respectively, are substantial enough to account for the order-of-magnitude-range of mRNA stabilities observed in wild-type cells.

Reviewer \#1:

It\'s unfortunate that they chose not to use ribo0 to deplete rRNA, as only a few percent of the total mRNA reads they obtained in the new experiments come from mRNA, and they claim that the relatively weak correlation between mRNA half-lives for total vs polyA selected mRNA is attributable in part to the low read depth for total RNA. Nevertheless, they find the same very short half-life for bulk total mRNA observed for bulk polyA(+) mRNA, which supports the validity of their measurements using polyA selected mRNAs.

There are remaining issues however concerning the changes in half-lives of specific mRNAs in response to different drugs or genetic manipulations. They did no significance testing on these measurements but based on the mean values and standard deviations provided for 3 biological replicates, my own application of a standard t-test indicates that the changes shown in Figure 3B for low-level CHX treatment are not statistically significant (p\>0.05) for any of the three mRNAs (ACT1, CIS3, RPL25). This is also the case for PDC1 and CIS3 in response to 3AT in Figures 3D and 3F (one of which was claimed to show a difference, but it wasn\'t indicated which one), for ACT1 and RPL25 in response to HIP in Figure 3I, and for ACT1 in response to the eIF4E/4G_down mutations in Figure 3J. It could be argued that the new measurements conducted on analysis of total RNA shown in Figure 3---figure supplement 3 can be used to bolster their conclusions, but these measurements were done for only a single biological replicate; moreover, the findings for total RNA for ACT1 again seem to show no difference in half-life for +/- CHX (panel B), and none as well for ACT1 and RPL25 in response to 3AT (panel D). (CIS3 is stabilized in panel D, but it\'s unclear whether CIS3 was judged to be stabilized in the polyA(+) measurements, as noted above.) Two additional replicates are needed for the total RNA measurements, allowing them to provide mean and SD values. In addition, they need to indicate which differences in Figure 3 and Figure 3---figure supplement.3 (once more replicates are conducted for the latter), have a P-value of \<0.05 in the appropriate significance test.

There are also issues with the new experiments added to show that the initiation rates of particular mRNAs are reduced in response to HIP or eIF4E/4G_down. It appears that the experiments were done only once, as there is no mention of data from replicates. Also, the data in panel D of Figure 3---figure supplement.5 for all three mRNAs are quite unexpected, as the mRNA levels are greatly reduced, and the ACT1 and CIS3 mRNAs actually do not shift to smaller polysomes, in response to eIF4E/4G_down. By comparison, the HIP treatment in panel B shows no substantial change in overall mRNA level despite similar decreases in half-life for these mRNAs in the two different treatments and does exhibit the expected shift of all 3 mRNAs to smaller polysomes. It needs to be shown that the results in panels B and D are reproducible in at least one replicate experiment, and the unexpected data for the eIF4E/4G_down experiment need to be discussed.

The median shifts in half-life for all mRNAs shown in Figures 3H and 3K are only 1-2 min on 3-AT or HIP treatment; and with CHX treatment, it appears that the shift is restricted to the mRNAs with the longest half-lives. It seems possible therefore that the effects of reduced initiation or elongation in decreasing or increasing mRNA stability, respectively, are not really strong enough to explain the order of magnitude range of mRNA stabilities observed in wild-type cells. Perhaps the authors should consider softening statements about initiation being the primary determinant of mRNA stability and instead identify it as one important determinant. Is it possible that on some mRNAs, the presence of suboptimal codons is equally important, with ribosomes containing empty A sites being recognized by Dhh1 in the manner suggested by Coller and Green? After all, two out of 12 mRNAs were found to decay faster, not slower, in the presence of 3AT; and presumably there are many other mRNAs behaving like these two mRNAs, in a manner consistent with the Coller/Green Dhh1 model.

\- Subsection "An improved non-invasive metabolic labeling protocol reveals that the yeast transcriptome is highly unstable": Perhaps step 7 is intended?

\- Subsection "An improved non-invasive metabolic labeling protocol reveals that the yeast transcriptome is highly unstable": Indicate the medium used, e.g. nutrient-rich medium with glucose as carbon source?

\- Figure 1---figure supplement 1 has 9 panels. Relevant panels should be cited individually in the text-otherwise the reader has to inspect the entire figure without the guidance of text to find the supporting results being cited. This should be fixed throughout the manuscript.

\- Subsection "An improved non-invasive metabolic labeling protocol reveals that the yeast transcriptome is highly unstable": The pool of polyadenylated mRNAs should be designated polyA(+) mRNA rather than polyA-mRNA, which could be interpreted as polyA(-).

\- Figure 1---figure supplement 2B: Indicate whether the correlation value of 0.44 is r or r2.

\- Subsection "Slowing translation elongation protects transcripts against degradation": Weinberg and Bartel showed that mRNA abundance is strongly correlated with translation efficiency, so the correlation with abundance could also be reflect the correlation of half-life with TE.

-Was Figure 2---figure supplement 1 cited in Results section?

\- Subsection "Slowing translation elongation protects transcripts against degradation" and Figure 3---figure supplement 1A and Figure 3B: It needs to be stated in Results section or at least Figure 3 legends that the data for the specific mRNAs was obtained by RT-qPCR quantification of mRNAs obtained from the mRNA stability profiling technique outlined in Figure 1. There are no error bars for the 50μg/ml CHX experiment in Figure 3---figure supplement 1A, indicating the apparent lack of replicates. As noted above, assuming that the error bars in Figure 3B (which were not defined in the legend) are the SD values for n=3, none of the differences in half-life for the 3 mRNAs in Figure 3B are statistically significant (p\<0.05) in an unpaired t-test. This is especially so for ACT1, where the points + and -- CHX essentially fall on the same curves. P-values for these differences need to provided in the figures or legends.

\- Subsection "Slowing translation elongation protects transcripts against degradation": Figure 3---figure supplement 6 is not the correct citation.

\- Subsection "Slowing translation elongation protects transcripts against degradation": The replicates are in Figure 3---figure supplement 2, not Figure 3---figure supplement 1; Are they citing Figure 3---figure supplement 1C? (This underscores the need to cite specific panels in the Figure supplements.

\- Subsection "Slowing translation elongation protects transcripts against degradation" and Figure 3---figure supplement 3B: The stabilization of ACT1 is not convincing. As noted above, it appears that the experiments on total mRNA in Figure 3---figure supplement 1A-C were done on only one replicate.

\- Subsection "Slowing translation elongation protects transcripts against degradation": Why then are the results for total vs polyA(+) mRNAs essentially the same at 0.2μg/ml CHX?

\- Subsection "Slowing translation elongation protects transcripts against degradation" and Figure 3D-G: As noted above, the results of a t-test show that the half-life differences conferred by 3AT are not significantly different for PDC1 and CIS3, but they claim that only one mRNA was unchanged without identifying it. Stipulate whether it\'s PDC1 or CIS3 that is judged to be unchanged.

\- Subsection "Slowing translation elongation protects transcripts against degradation": Indicate the number of Gly codons for the mRNAs in Figure 3E-G.

\- Subsection "Slowing translation elongation protects transcripts against degradation" and Figure 3---figure supplement 3D: This statement is not likely to be true for ACT1, which appears to be unresponsive to 3AT in total RNA.

\- Subsection "Inhibition of translation initiation destabilizes individual transcripts" and Figure 3I: As noted above, the results of a t-test show that the half-life differences conferred by HIP are not significantly different for ACT1 and RPL25. Destabilization of ACT1 and RPL25 mRNA appears to have occurred in total RNA (Figure 3---figure supplement 3E) but replicates would be needed if these results will be used to bolster the conclusions for these two mRNAs in polyA(+) RNA.

-Figure 3---figure supplement 5A-B: They claim that *S. pombe* cells were added for the polysome separation. Were these cells also treated with hippuristanol? If not, then presumably the reductions in polysomes conferred by HIP is even larger than indicated. This needs to be explained better in the legend. As noted above, the experiments in panels A-D appear to have been done only once, with no biological replicates. In addition, in Figure 3---figure supplement 5C-D: It\'s surprising that only RPL25 shows a shift to smaller polysomes, whereas ACT1 and CIS3, if anything, exhibit a shift to larger polysomes in the eIF4E/Gdown cells, which is not expected for a defect in initiation. In addition, the overall levels of the transcripts are greatly reduced here, but not in the HIP treated cells shown in panel B, despite similar effects of the two treatments on mRNA half-life shown in Figure 3I-J.

\- Subsection "Translation elongation and initiation globally affect mRNA half-lives": The median shifts in half-life are only 1-2 min on 3-AT treatment of HIP treatment in Figures 3H and 3K; and with CHX, it appears that the shift is restricted to the mRNAs with the longest half-lives. Given that mRNA half-lives vary over more than an order of magnitude, it\'s unclear that the changes in half-lives of 1-2 min conferred by substantially inhibiting initiation or elongation rates are adequate to explain the natural range in half-lives.

\- Subsection "Inhibition of translation initiation induces processing bodies": Stipulate that the marker for SGs is Pab1 (I presume) and cite the relevant panel of Figure 4---figure supplement 1. Explain better the dhh1 mutants analyzed in panel C.

Subsection "Inhibition of translation initiation induces processing bodies": Explain better what \"slowly decaying PP7 stem loops\" means and indicate where they are located in the mRNA.

\- Discussion section: The logic here is unclear. In Pgal shut-off experiments, cells are shifted to glucose to shut off new synthesis and the amounts of the remaining mRNAs are followed by Northerns. Growth in glucose is not stressful, but it could be that the carbon source shift per se alters the level or function of the decay machinery. I don\'t see how effects of GC-content on transcription would affect the measurements of half-lives by this approach.

\- Discussion section: This conclusion needs to be elaborated as it is not self-evident.

Reviewer \#2:

I agree with reviewer 1 that in an ideal world the authors would had employed an rRNA subtraction procedure such as ribo0, in addition to the total RNA analysis, as this would have allowed them to recover far more mRNA reads. Nonetheless, the data do argue strongly against the possibility that the discrepancies between the authors\' mRNA half life data and previous studies was simply an artifact of looking at polyA selected mRNAs. This experiment and the expanded discussion thus address the major concern I had with the original submission.

Reviewer \#3:

I find the manuscript to be significantly improved, and the authors have done an excellent job of addressing the first round of comments. I am now supportive of publication.

10.7554/eLife.32536.079

Author response

> Summary:
>
> Chan et al. present an improved method for measuring the kinetics of mRNA synthesis and degradation that minimizes perturbation of cellular state and that accounts for various potential sources of non-biological variation. They apply this method to measure the half-lives of each type of mRNA in yeast and produce results that are strikingly different from those produced by earlier approaches. In particular, they find that average half-lives are substantially shorter than previously measured. Seeking to explain gene-by-gene variation in mRNA stability, the authors identify rates of translation initiation and optimal codon content as having similarly strong positive correlations with half-life. To distinguish between the more historical model in which the presence of ribosomes protects messages from decay machinery and a newer model in which slow elongation (e.g. of non-optimal codons) serves as a general trigger of decay, the authors measure mRNA stability after applying a variety of chemical and genetic methods of interfering with elongation or with initiation. They find that slow elongation stabilizes mRNA, while slow initiation destabilizes mRNA, favoring a model in which competition for access to the cap, rather than sensing of slow moving ribosomes, serves as the primary gatekeeper for decay pathways.
>
> Essential revisions:
>
> The most important issue to be addressed is whether your use of poly(A) selection has led you to measure the half-lives of only a fraction of mRNAs with poly(A) tails long enough for oligo-dT selection or, in the limit case, to measure rates of deadenylation only. It is necessary that you alter your technique to avoid poly(A) selection by using ribo0 depletion as an alternative approach and determine whether your major conclusions about mRNA half-lives and the relatively greater importance of translation initiation versus elongation rates in determining half-lives still hold.

To address this important issue, we have now performed decay experiments in the complete absence of any mRNA enrichment by analyzing total RNA samples. We opted for this approach --instead of ribo0- to avoid any potential bias that could be introduced by a selection step. Overall, these new measurements confirm our prior conclusions. First, using transcriptome-wide decay profiling we find that the transcriptome has almost identical average and median half-lives with very similar shaped distributions in the unselected and poly(A)-selected datasets supporting our finding that the transcriptome is shorter lived than most previous measurements have found. On an individual transcript level, we do observe differences between the two datasets. We show that this is in part due to lower sequencing coverage in the unselected samples and but also partly reveals true biological differences likely in steps downstream of deadenylation.

Second, we have gone back and reanalyzed all of the translational perturbation experiments in the absence of any mRNA enrichment. Again, these new results are entirely consistent with the polyA selected data, and if anything, we find more exaggerated effects, especially in the presence of the elongation inhibitors cycloheximide and sordarin (as was pointed out by reviewer 3).

> Second, the reviewers were not convinced of the statistical significance of differences in half-lives of specific mRNAs being claimed in the Results, requiring more thorough documentation of replicates with the appropriate statistical analyses.

We have included all biological replicates and computed average half-lives with standard deviations and indicated changes in half-life that were statistically significant. We have also included P-values for all comparative cumulative histograms in the Results section to quantify the significance of the differences observed.

> Third, because your most significant results at odds with the previous model positing that mRNA decay is triggered by stalled ribosomes containing an empty A-site came from analyzing turnover rates in gcn2 cells treated with 3AT, this approach should be conducted genome-wide to analyze the correlation (or lack thereof) between ribosome stalling at His codons and mRNA half-life.

As requested we performed a transcriptome-wide profile of mRNA half-lives in the presence and absence of 3AT. We find that there is significant stabilization of mRNAs across the transcriptome in 3AT treated cells, strengthening our prior conclusion. This analysis also suggests there is a thresholding effect where a minimal number of histidine and glycine codons must be present for a strong stabilization effect to be observed.

> Fourth, for the experiments using hippuristanol or dominant-negative eIF4E/degron depletion of eIF4E to inhibit translation initiation, it should be verified that the translation initiation rate was reduced for the specific mRNAs whose half-lives are being measured.

To our knowledge translation initiation rates were never been directly measured in vivo. Instead we have therefore performed as suggested by reviewer 1, polysome fractionation in both hippuristanol-treated cells and in the double eIF4E/G mutant and analyzed how *ACT1, CIS3* and *RPL25* mRNAs partition in the polysome in treated and untreated conditions. We find that in the case of hippuristanol treatment, ribosomes are redistributed from heavy polysome fractions to the lighter fractions. This redistribution is also seen for specific mRNAs that were examined. In the case of the eIF4E/G double mutant, we find that overall polysome abundance is attenuated and this is once again mirrored for the specific transcripts.

> Fifth, additional revisions of the text are required to reconcile your model with the results of previously published experiments on reporter mRNAs that provided strong evidence that codon optimality is a strong determinant of mRNA half-life, which would suggest that this mRNA feature has not merely co-evolved with translation initiation efficiency in the manner you suggest.

We have included a broader discussion of the possible sources of discrepancy between our observations and previous observations regarding codon optimality. This also includes a discussion of more recent work that has shown that altering codon usage in a model transcript often leads to increased GC content which in turn accelerates transcription which can falsely lead to perceived "stabilization" of a transcript due to higher steady state abundances.

> Sixth, it seems necessary to address the alternative interpretation of your experiments on P-bodies raised by reviewer \#1.

We have expanded our discussion of the site of mRNA decay in the cell and have tried to provide are more multifaceted and nuanced interpretation of these experiments. We try to make explicit that we view mRNA decay occurring not just in P-bodies and the polysome but we reason --also based on other recent publications on this topic- that neither of these sites are likely the primary sites of mRNA decay and that it is more likely that most mRNA turnover occurs in sub-microscopic decay mRNPs.

> Reviewer \#1:
>
> This paper describes an improved, non-invasive method for genome-wide measurements of mRNA half-lives in growing yeast cells. The results suggest that mRNA half-lives are between 3-fold and 26-fold shorter than determined previously by other approaches relying on metabolic labeling or inhibition of transcription, respectively. By examining the effects of inhibiting translation elongation or initiation on mRNA half-lives in various ways, that conclude that the rate of translation initiation is a more important determinant of mRNA half-life than is the rate of elongation, at odds with recent reports from the Coller and Green labs indicating that codon optimality is the principle determinant of mRNA stability of native mRNAs in budding yeast. They provide evidence that stalling ribosomes during elongation with the inhibitors cycloheximide or sordorin, or by starving for the amino acid histidine, tends to decrease rather than increase rates of mRNA turnover, presumably by having stalled ribosomes protect the mRNA from nucleolytic digestion, rather than inducing turnover via Dhh1 recognition of stalled ribosomes as recently concluded by Coller and Green. By contrast, an inhibitor of eIF4A or mutants that reduce eIF4F function and presumably produce a global decrease in the initiation rate lead to increased mRNA turnover. Thus, they propose that the rate of initiation is the key determinant of mRNA stability, with a reduction in initiation either exposing the mRNA cap to the decapping machinery or decreasing ribosome densities on coding regions. Based on the fact that inhibiting eIF4A with hippuristanol (HIP) induces Dhh1-dependent P-bodies, and that the abundance of a stem-loop reporter mRNA in P bodies decayed over time, they propose that inhibiting initiation sends mRNAs to P bodies and that this is, or can be, the site of their decay.
>
> \- The differences in half-life claimed for ACT1 and CIS3 mRNAs in response to CHX treatment in Figure 3---figure supplement 1 and Figure 3B are unconvincing, and they have provided no half-life values for these experiments. The claim that RPS2, RPL25, CIS3 and OSW5 mRNAs exhibit slower turnover on 3AT treatment are similarly unconvincing.

As discussed in our response to point (2) above, we have now computed average half-lives with standard deviations for these experiments. This analysis revealed that *CIS3* is not significantly stabilized in the presence of 3AT, and we have modified the results to reflect this.

> \- The most significant results presented here that are at odds with the proposal of Coller/Green, that decay is triggered by stalled ribosomes containing an empty A-site, came from analyzing turnover rates in gcn2 cells treated with 3AT to induce histidine starvation and attendant stalling by elongating ribosomes at histidine codons genome-wide. The experiments using CHX or sordorin are not relevant because these drugs do not stall ribosomes with an empty A site. As such, in order to justify their claim that inhibiting elongation in this manner slows down rather than accelerates mRNA decay on a genome-wide level, it is necessary to obtain mRNA turnover data for the entire transcriptome using their technique in 3AT-treated gcn2 cells, rather than examining only a dozen mRNAs by RT-qPCR. In addition, because the previous ribosome profiling experiments using 3AT carried out in the Green lab, which they cite for the effect of 3AT in stalling ribosomes, employed a GCN2+ strain, it is necessary that they confirm that treating a gcn2 mutant with 3AT will cause a similar (or even greater) degree of pauses at histidine codons by elongating ribosomes, and to demonstrate a widespread lack of correlation between pausing at histidine codons measured by ribosome profiling and mRNA half-lives measured by their technique in 3AT-treated cells.

Please see our response to point (3) above.

> \- The authors have used treatment with hippuristanol (HIP), or overexpression of a dominant-negative eIF4E variant lacking cap-binding activity together with degron depletion of eIF4E, as alternative means to inhibit global translation initiation rates. However, they have relied only on cell growth assays to document these effects. It is necessary to show by a more direct assay that translation initiation is impaired for the specific mRNAs whose half-lives are being measured (ACT1, CIS3, and RPL25). The best approach would be to show that the average number of ribosomes per mRNA is reduced on these mRNAs by the treatments shown in Figure 3H-I by probing for these mRNAs across fractionated polysomes; the effects on abundance and average size of bulk polysomes will be obtained in parallel. Alternatively, they could show that the amounts of these mRNAs associated with eIF4G (RNA-IP) are reduced by the two treatments. Treatment with sordarin or CHX would be a key negative control for either approach.

Please see our response to point (4) above.

> \- In Figure 3---figure supplement 2C-D, there are unexplained increases in synthesis of RPL25 in response to CHX and sordorin that require comment.

We hesitate to propose some sort of ribosomal protein gene feedback mechanism as it is well outside the scope of this manuscript and have thus opted to not make such an addition.

> \- The interpretation of the results in Figure 4E, that the reporter mRNA is being degraded in P-bodies, seems to overlook the possibility that the reporter mRNA exchanges rapidly between P-bodies and other compartments, in which case it could be degraded elsewhere, e.g. on polysomes, and its abundance in P-bodies would merely indicate the overall cellular level of the transcript. Is there a way to eliminate this alternative?

Please see our response to point (6) above.

> \- The validity of this method for measuring mRNA half-lives depends on highly efficient incorporation of 4-thioU into all newly synthesized mRNAs, and also highly efficient separation of these mRNAs from the un-labeled mRNAs pre-existing before the 4-thioU pulse, as it is the decay of the later over time that is quantified to determine half-lives. Extracting decay rates from the data requires a theoretical model for the decay, which includes an \"efficiency parameter\". It is difficult to assess the validity of this model, and hence, the mRNA half-lives determined using it. This is worrisome because their measured half-lives are 3-fold shorter than those measured by other labs using non-invasive metabolic labeling, and there is no attention given to resolving these discrepancies. The authors have provided and extended technical supplement on the refinement of their technique, but it seems important to provide justification for the validity of the modeling and method for extracting turnover times in the main text of the paper.

We have extended our discussion of the justification of an efficiency parameter in the main text but reserve the full discussion to the extended technical supplement as this important but technical point would distract from the biological questions the manuscript is attempting to address. We would also point out that the gold standard for metabolic labeling to date which is 14C-adenosine incorporation agrees very well with our observations.

> Reviewer \#2:
>
> Chan et al. present an improved method for measuring the kinetics of mRNA synthesis and degradation that minimizes perturbation of cellular state and that accounts for various potential sources of non-biological variation. They apply this method to measure the half-lives of each type of mRNA in yeast and produce results that are strikingly different from those produced by earlier approaches. In particular, they find that average half-lives are substantially shorter than previously measured. Seeking to explain gene-by-gene variation in mRNA stability, the authors identify rates of translation initiation and optimal codon content as having similarly strong positive correlations with half-life. To distinguish between the more historical model in which the presence of ribosomes protects messages from decay machinery and a newer model in which slow elongation (e.g. of non-optimal codons) serves as a general trigger of decay, the authors measure mRNA stability after applying a variety of chemical and genetic methods of interfering with elongation or with initiation. They find that slow elongation stabilizes mRNA, while slow initiation destabilizes mRNA, favoring a model in which competition for access to the cap, rather than sensing of slow moving ribosomes, serves as the primary gatekeeper for decay pathways.
>
> This is important work that has been carefully designed and executed. The unexpectedly strong connection between codon optimality and mRNA decay has emerged as a major area of research over the last three years, and intense efforts are underway to understand the molecular mechanisms that underpin this connection. By calling into question one of the central assumptions of this new sub-field (namely, that slowing down elongation should destabilize mRNA), Chan et al., trigger a messy but necessary rethinking of our understanding of these phenomenon.
>
> 1\) Presnyak et al., 2015 argues that enriching for mRNA by polyA pulldown produces artificially depressed estimates of half-lives due to the existence of stable deadenylated messages. Why did the authors use polyA pulldown in their protocol? Could this effect contribute to the shorter half-lives they observe? (It is unclear exactly which datasets from this paper are the two Coller datasets in Figure 1---figure supplement 1G.)

Please see our response to point (1) above.

> 2\) The authors argue that, given their results, the observed positive correlation between optimal codon content and half-life is likely to be due to co-evolution rather than direct causal connection. Several papers (PMIDs: 25768907, 27436874, 27641505, and others), however, have presented compelling evidence for a direct causal connection by showing that systematically deoptimizing the codon content of a reporter construct systematically reduces its stability. To some extent, the authors\' results contradict the standard interpretation of these published experiments. The paper would be strengthened if the authors engaged with this contradiction head-on by more thoroughly discussing exactly which ideas in this field are and are not consistent with their new data.

Please see our response to point (5) above.

> Reviewer \#3:
>
> This manuscript addresses the relationship between steps in translation and mRNA degradation in yeast. The manuscript addresses an important and timely issue in the field: Is decay rate coupled to stalled ribosomes, or to poor translation initiation? This has become an issue because of two competing lines of work. First, previous work using reporter mRNAs showed that translation initiation was in competition with decay (both deadenylation and decapping). However, more recent work, using both genome wide analyses and reporter mRNAs has argued that inefficient translation elongation (as defined by non-optimal codons) is the predominant driver of mRNA decay rates. Thus, resolving this issue will be important for understanding mRNA decay control.
>
> The strength of this manuscript is that is uses genome wide analyses of mRNA decay rates both under normal conditions, and with perturbations that affect ribosome elongation rates or translation initiation rates. The main conclusion from the work is that slow ribosome movement actually stabilizes mRNAs, while decreasing translation initiation increases mRNA degradation. This is a useful contribution and worthy of consideration for publication in eLife, although there are substantive issues that should be addressed before publication.
>
> 1\) The biggest issue with the manuscript is that the procedure for mRNA decay rates involves an oligo(dT) selection step. Since many mRNAs in yeast exist at steady state as oligoadenylated or deadenylated mRNAs (see Herrick et al., 1990 MCB), this only selects for a substep of mRNAs (typically with A tails longer than 30). Thus, the approach is really only measuring the deadenylation rate of mRNAs and not overall decay. This is presumably why their decay rates are faster than what has been described previously using methods that do not rely on selection of A+ mRNA species. The best approach for the authors here would be to repeat the experiments using ribo0 RNA, which would allow them to access the full mRNA decay pathway. Alternatively, they could re-write the manuscript as simply studying deadenylation, but this would diminish the impact of the work.

Please see our response to point (1) above.

> 2\) In Figure 3B, the differences in decay curves are slight and would need to be supported by error bars to convince the reader these are meaningful. In fact, the data might be more convincing if decay rate was measured with ribo0 RNA since previous work (Beelman and Parker, 1995 and others) had shown cycloheximide primarily inhibits decapping with little effect on deadenylation rate.

Please see our response to point (2) above.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> All three reviewers agreed that the paper has been significantly improved by the new experiments that were carried out, as well as the revisions of text; and your efforts to address all of the major criticisms of the first version were greatly appreciated. In particular, the new genome-wide data obtained from analyzing total RNA generally supports the conclusions reached from poly(A) selection, which resolves the most important criticism of the original version of the paper.

Thank you and we agree that the new genome-wide data have strengthened our manuscript.

> There are, however, some remaining issues that require your attention, raised by reviewer \#1, including the lack of statistical significance of small differences in mRNA half-lives for certain mRNAs, and the apparent lack of any replicates for the new half-life measurements conducted with total RNA. There is also an objection to your interpretation of the new results presented to establish a shift to smaller polysomes of mRNAs in response to down-regulating eIF4E/4G; and a concern that these experiments might have been conducted only once without replication. It is felt that these shortcomings detract from the overall scientific quality of the work and do not satisfy the journal\'s rigorous standards for replicate measurements and statistical analyses of data. Finally, you have been asked to consider whether the magnitude of the observed effects of reducing initiation or elongation in decreasing or increasing mRNA stabilities, respectively, are substantial enough to account for the order-of-magnitude-range of mRNA stabilities observed in wild-type cells.

In response to this, we have subjected our individual transcript measurements to a more rigorous statistical analysis and we have found that the majority of our measurements support a model where competition with translation initiation determines the stability of an mRNA. None of our results refute this model. Furthermore, we have found no evidence for the stalled ribosome leading to mRNA decay model. In light of this analysis and the lack of ambiguity in our findings, we would argue that further biological replicates for the same experiments using total RNA (rather than polyA selected mRNA) would only serve to delay publication of this manuscript.

Furthermore, we have removed the polysome analysis from the main paper and included it only as a figure in response to reviewers as this was an experiment that was originally requested by comments of reviewer 1. This experiment only serves to bolster the assertion that translation is attenuated in hippuristanol treated cells and in eIF4E/G^down^ mutant cells, which we have already demonstrated clear growth defects for. Moreover, repeating the hippuristanol experiment is not a simple matter as this drug is not commercially available. These experiments require large amount of drug and the small amount that we have was a generous gift of our collaborator, Junichi Tanaka, who unfortunately could not provide us with more hippuristanol at this point.

Lastly, given the results of our statistical analysis, we decided against softening our conclusions. However, we have included an extensive discussion where we attempt to account for the differences between the Coller group conclusions and our findings.

> Reviewer \#1:
>
> It\'s unfortunate that they chose not to use ribo0 to deplete rRNA, as only a few percent of the total mRNA reads they obtained in the new experiments come from mRNA, and they claim that the relatively weak correlation between mRNA half-lives for total vs polyA selected mRNA is attributable in part to the low read depth for total RNA. Nevertheless, they find the same very short half-life for bulk total mRNA observed for bulk polyA(+) mRNA, which supports the validity of their measurements using polyA selected mRNAs.

We opted to analyze total RNA to avoid any biases that are introduced by RNA selection methods, and we concur that our new analysis fully supports the validity of our initial measurements.

> There are remaining issues however concerning the changes in half-lives of specific mRNAs in response to different drugs or genetic manipulations. They did no significance testing on these measurements but based on the mean values and standard deviations provided for 3 biological replicates, my own application of a standard t-test indicates that the changes shown in Figure 3B for low-level CHX treatment are not statistically significant (p\>0.05) for any of the three mRNAs (ACT1, CIS3, RPL25). This is also the case for PDC1 and CIS3 in response to 3AT in Figures 3D and 3F (one of which was claimed to show a difference, but it wasn\'t indicated which one), for ACT1 and RPL25 in response to HIP in Figure 3I, and for ACT1 in response to the eIF4E/4G_down mutations in Figure 3J. It could be argued that the new measurements conducted on analysis of total RNA shown in Figure 3---figure supplement 3 can be used to bolster their conclusions, but these measurements were done for only a single biological replicate; moreover, the findings for total RNA for ACT1 again seem to show no difference in half-life for +/- CHX (panel B), and none as well for ACT1 and RPL25 in response to 3AT (panel D). (CIS3 is stabilized in panel D, but it\'s unclear whether CIS3 was judged to be stabilized in the polyA(+) measurements, as noted above.) Two additional replicates are needed for the total RNA measurements, allowing them to provide mean and SD values. In addition, they need to indicate which differences in Figure 3 and Figure 3---figure supplement 3 (once more replicates are conducted for the latter), have a P-value of \<0.05 in the appropriate significance test.

We thank the reviewer for encouraging us to consider our data in a more rigorous statistical framework. Since all drug treatment experiments were performed by collecting a treated and mock treated sample at the same time, we have used a paired t-test and to allow for hypothesis testing of the two models of decay determination (ribosome stalling vs translation factor protection), we have sampled from a one-tailed distribution. We have included all P-values in a revised Figure 3. In summary, 21 of 27 measurements (lowCHX: CIS3, RPL25; SOR: ACT1, CIS3, RPL25; 3AT: CYS4, DED1, CIS3, RPL25, AIM7, AIM13, RPS2, NPA3, PAM16, RPC11, VMA21; HIP: ACT1, CIS3, RPL25; eIF4E/G: ACT1, CIS3) have p-values less than 0.05 in support of the prediction of the translation factor protection model. 6 of the measurements (lowCHX: ACT1; 3AT: ACT1, PDC1, OSW5, TPI1; eIF4E/G: RPL25) have p-values greater than 0.05 and therefore cannot be said to be statistically significant. In contrast, 0 of the 21 measurements testing the stalled ribosome model have p-values less than 0.05 (we excluded the HIP and eIF4E/G measurements from this analysis since the stalled ribosome model does not make a prediction for these experiments). Thus, we conclude that the majority of our data support the translation-factor protection model and none of the data we have collected support the stalled ribosome-triggered decay model. We have included the additional statistical analyses in the text and Figure of a revised manuscript.

Furthermore, we would like to point out that these small-scale experiments are significantly bolstered by the transcriptome-wide analyses that are presented in the manuscript and the global trends are completely in line with our small-scale experiments. Moreover, the effect we have observed with cycloheximide has been previously reported (Beelman and Parker, 1994). In addition, the experiments measuring mRNA stability in the absence of polyA selection were performed in response to reviewers' comments and were only included as a supplemental figure. Given the statistical analysis described above and given that none of the trends change (and if anything, are further exacerbated for certain experiments such as the 50 μg/mL cycloheximide and sordarin experiments), we would argue that further biological replicates would not add significant value to the manuscript and would only serve to further delay the publication of this work.

> There are also issues with the new experiments added to show that the initiation rates of particular mRNAs are reduced in response to HIP or eIF4E/4G_down. It appears that the experiments were done only once, as there is no mention of data from replicates. Also, the data in panel D of Figure 3---figure supplement 5 for all three mRNAs are quite unexpected, as the mRNA levels are greatly reduced, and the ACT1 and CIS3 mRNAs actually do not shift to smaller polysomes, in response to eIF4E/4G_down. By comparison, the HIP treatment in panel B shows no substantial change in overall mRNA level despite similar decreases in half-life for these mRNAs in the two different treatments and does exhibit the expected shift of all 3 mRNAs to smaller polysomes. It needs to be shown that the results in panels B and D are reproducible in at least one replicate experiment, and the unexpected data for the eIF4E/4G_down experiment need to be discussed.

We would like to respectfully disagree that the lower overall mRNA levels in eIF4E/G are unexpected. The effect of attenuated eIF4A is likely not a complete block in initiation as cap recognition is still possible and the importance of eIF4A in efficient translation is likely transcript specific as suggested by papers of the Ingolia, Fanidi and Hinnebusch groups. In limiting hippuristanol where eIF4A is partially inhibited, one would expect that without full helicase activity, ribosomes would likely kinetically pile up during the scanning phase prior to AUG recognition and a shift from heavier polysomes to lighter polysomes would be expected. This is indeed what is observed. However, in the eIF4E/G mutant, both the cap binding subunit as well as the scaffolding subunit are attenuated but all other translation initiation machinery is intact and functional and thus any ribosome that loads onto an mRNA should behave normally. Given the critical role of the pioneer translation initiation round for sustained translation cycles (reviewed by Maquat, Tarn and Isken, 2011), general mRNA attenuation in the polysome is a logical outcome.

The original purpose of this figure was to address a reviewer's comment that an independent means of verifying translation attenuation other than reduced growth was required. The data presented have clearly demonstrated that translation is indeed defective.

With respect to biological replication, this is currently not feasible as this experiment requires a large amount of hippuristanol, which had received only a limited amount from a generous collaborator. Moreover, as we performed this experiment to address a reviewer's concerns we decided to exclude this figure from the main manuscript and now only include it in the response to reviewer's comments. We feel this is appropriate as the in depth discussion of the results of this experiment are not at all the focus of this paper and would only serve to distract and dilute the main points of the manuscript.

> The median shifts in half-life for all mRNAs shown in Figure 3H and 3K are only 1-2 min on 3-AT or HIP treatment; and with CHX treatment, it appears that the shift is restricted to the mRNAs with the longest half-lives. It seems possible therefore that the effects of reduced initiation or elongation in decreasing or increasing mRNA stability, respectively, are not really strong enough to explain the order of magnitude range of mRNA stabilities observed in wild-type cells. Perhaps the authors should consider softening statements about initiation being the primary determinant of mRNA stability and instead identify it as one important determinant. Is it possible that on some mRNAs, the presence of suboptimal codons is equally important, with ribosomes containing empty A sites being recognized by Dhh1 in the manner suggested by Coller and Green? After all, two out of 12 mRNAs were found to decay faster, not slower, in the presence of 3AT; and presumably there are many other mRNAs behaving like these two mRNAs, in a manner consistent with the Coller/Green Dhh1 model.

As was previously requested by a reviewer, we have presented the significance values for the transcriptome-wide data and the p-values indicate significance. Moreover, in light of the statistical analysis of the single decay plots which revealed that the large majority of our measurements are in significant support of the translation-factor protection model, none of our unbiased experiments argue against the translation-factor protection model and importantly, none of our measurements came out in support of the ribosome-triggered decay model, we feel that it would be inappropriate to soften our claims or suggest that ribosome-stalling plays a role in general mRNA decay rate determination. We have suggested in the discussion that this model may make more sense in the stress conditions that were used to measure mRNA stability of engineered transcripts or for select individual transcripts.

We would also like to reiterate that we are not proposing a new model in this manuscript. Rather, we are testing in an unbiased manner two prevailing theories of how mRNA stability is determined. We have found that our data support the model proposed by Parker and others in the 1990s which is based on data gathered from multiple types of experiments where translation initiation is perturbed either in cis or in trans and mRNA stability was found to be decreased (see Beelman and Parker, 1994, Schwartz and Parker, 1999 and LeGrandeur and Parker, 1999). Furthermore, our data are the first to contradict a stalled ribosome-triggered decay model. Studies using mutant tRNAs to induce ribosome pausing during elongation have shown that this leads to stabilization of mRNAs (Peltz, Donahue and Jacobson, 1992 and Zuk, Belk and Jacobson, 1999). Moreover, we have presented a fair discussion attempting to resolve the differences between our experiments and those of Coller/Green.

With respect to magnitude, we intentionally chose doses of drug treatments that had modest effects on cell physiology. Indeed, when strong doses are employed as in the case of high doses of cycloheximide, we and others previously have reported dramatic effects on mRNA stabilization. However, we wished to measure half-lives in cells that were not completely shut down and therefore chose drug doses that were well below lethal levels. We would contrast this with the methods of Coller/Green where artificial, model mRNAs are codon deoptimized well below any observed codon optimality found in the transcriptome.

> \- Subsection "An improved non-invasive metabolic labeling protocol reveals that the yeast transcriptome is highly unstable": Perhaps step 7 is intended?

We have updated the text to resolve this ambiguity.

> \- Subsection "An improved non-invasive metabolic labeling protocol reveals that the yeast transcriptome is highly unstable": Indicate the medium used, e.g. nutrient-rich medium with glucose as carbon source?

We provide a complete formulation of the media used in the Materials and methods section. To do so in the body of the text would be disruptive.

> \- Figure 1---figure supplement 1 has 9 panels. Relevant panels should be cited individually in the text-otherwise the reader has to inspect the entire figure without the guidance of text to find the supporting results being cited. This should be fixed throughout the manuscript.

We agree and have fixed this issue.

> \- Subsection "An improved non-invasive metabolic labeling protocol reveals that the yeast transcriptome is highly unstable": The pool of polyadenylated mRNAs should be designated polyA(+) mRNA rather than polyA-mRNA, which could be interpreted as polyA(-).

We thank the reviewer for the feedback and have changed this.

> \- Figure 1---figure supplement 2B: Indicate whether the correlation value of 0.44 is r or r2.

The value is presented as Pearson correlation, which is by definition r. We have now indicated that the value is r in the figure.

> \- Subsection "Slowing translation elongation protects transcripts against degradation": Weinberg and Bartel showed that mRNA abundance is strongly correlated with translation efficiency, so the correlation with abundance could also be reflect the correlation of half-life with TE.

We agree that all of these parameters correlate with one another. We present one possible explanation of one of these correlations, but we do not draw any conclusions as this is merely correlation and causation cannot be implied.

> \- Was Figure 2---figure supplement 1 cited in Results section?

It is only cited in the Discussion section. We did not include this in the Results section as this translation initiation rate dataset was derived using a kinetic model and is not a result of direct initiation rate measurements. Thus we did not deem it fair to include in the analysis in the main Figure 2.

> \- Subsection "Slowing translation elongation protects transcripts against degradation" and Figure 3---figure supplement 1A and Figure 3B: It needs to be stated in Results section or at least Figure 3 legends that the data for the specific mRNAs was obtained by RT-qPCR quantification of mRNAs obtained from the mRNA stability profiling technique outlined in Figure 1. There are no error bars for the 50μg/ml CHX experiment in Figure 3---figure supplement 1A, indicating the apparent lack of replicates. As noted above, assuming that the error bars in Figure 3B (which were not defined in the legend) are the SD values for n=3, none of the differences in half-life for the 3 mRNAs in Figure 3B are statistically significant (p\<0.05) in an unpaired t-test. This is especially so for ACT1, where the points + and -- CHX essentially fall on the same curves. P-values for these differences need to be provided in the figures or legends.

This has been addressed as discussed above.

> \- Subsection "Slowing translation elongation protects transcripts against degradation": Figure 3---figure supplement 6 is not the correct citation.

The citation refers to the titration of cycloheximide to a sub-lethal dose, which is Figure 3---figure supplement 6H. The new in text citation of subpanels in the supplemental figures hopefully clarifies this.

> \- Subsection "Slowing translation elongation protects transcripts against degradation": The replicates are in Figure 3---figure supplement 2, not Figure 3---figure supplement 1; Are they citing Figure 3---figure supplement 1C? (This underscores the need to cite specific panels in the Figure supplements.

As stated above, we have fixed this issue.

> \- Subsection "Slowing translation elongation protects transcripts against degradation" and Figure 3---figure supplement 3B: The stabilization of ACT1 is not convincing. As noted above, it appears that the experiments on total mRNA in Figure 3---figure supplement 1A-C were done on only one replicate.

We have addressed and discussed this issue above.

> \- Subsection "Slowing translation elongation protects transcripts against degradation": Why then are the results for total vs polyA(+) mRNAs essentially the same at 0.2μg/ml CHX?

Thank you, we have clarified the language.

> \- Subsection "Slowing translation elongation protects transcripts against degradation" and Figure 3D-G: As noted above, the results of a t-test show that the half-life differences conferred by 3AT are not significantly different for PDC1 and CIS3, but they claim that only one mRNA was unchanged without identifying it. Stipulate whether it\'s PDC1 or CIS3 that is judged to be unchanged.

We have addressed and discussed this issue above.

> \- Subsection "Slowing translation elongation protects transcripts against degradation": Indicate the number of Gly codons for the mRNAs in Figure 3E-G.

We have included glycine and histidine amino acid contents for all transcripts in Figure 3E-G.

> \- Subsection "Slowing translation elongation protects transcripts against degradation" and Figure 3---figure supplement 3D: This statement is not likely to be true for ACT1, which appears to be unresponsive to 3AT in total RNA.

We did not find that using unselected mRNA altered the stability measurement for ACT1. Therefore, the statement that the "results were recapitulated" seems valid.

> \- Subsection "Inhibition of translation initiation destabilizes individual transcripts" and Figure 3I: As noted above, the results of a t-test show that the half-life differences conferred by HIP are not significantly different for ACT1 and RPL25. Destabilization of ACT1 and RPL25 mRNA appears to have occurred in total RNA (Figure 3---figure supplement 3E) but replicates would be needed if these results will be used to bolster the conclusions for these two mRNAs in polyA(+) RNA.

We have addressed and discussed this issue above.

> \- Figure 3---figure supplement 5A-B: They claim that S. pombe cells were added for the polysome separation. Were these cells also treated with hippuristanol? If not, then presumably the reductions in polysomes conferred by HIP is even larger than indicated. This needs to be explained better in the legend. As noted above, the experiments in panels A-D appear to have been done only once, with no biological replicates. In addition, in Figure 3---figure supplement 5C-D: It\'s surprising that only RPL25 shows a shift to smaller polysomes, whereas ACT1 and CIS3, if anything, exhibit a shift to larger polysomes in the eIF4E/Gdown cells, which is not expected for a defect in initiation. In addition, the overall levels of the transcripts are greatly reduced here, but not in the HIP treated cells shown in panel B, despite similar effects of the two treatments on mRNA half-life shown in Figure 3I-J.

We have addressed and discussed this issue above.

> \- Subsection "Translation elongation and initiation globally affect mRNA half-lives": The median shifts in half-life are only 1-2 min on 3-AT treatment of HIP treatment in Figures 3H and 3K; and with CHX, it appears that the shift is restricted to the mRNAs with the longest half-lives. Given that mRNA half-lives vary over more than an order of magnitude, it\'s unclear that the changes in half-lives of 1-2 min conferred by substantially inhibiting initiation or elongation rates are adequate to explain the natural range in half-lives.

We have addressed and discussed this issue above.

> \- Subsection "Inhibition of translation initiation induces processing bodies": Stipulate that the marker for SGs is Pab1 (I presume) and cite the relevant panel of Figure 4---figure supplement 1. Explain better the dhh1 mutants analyzed in panel C.

The marker for SGs is indicated in the figure. We have extended the explanation of the *dhh1* mutants in the text.

> Subsection "Inhibition of translation initiation induces processing bodies": Explain better what \"slowly decaying PP7 stem loops\" means and indicate where they are located in the mRNA.

We tried to explain this better in the revised text.

> \- Discussion section: The logic here is unclear. In Pgal shut-off experiments, cells are shifted to glucose to shut off new synthesis and the amounts of the remaining mRNAs are followed by Northerns. Growth in glucose is not stressful, but it could be that the carbon source shift per se alters the level or function of the decay machinery. I don\'t see how effects of GC-content on transcription would affect the measurements of half-lives by this approach.

Growth is glucose is not stressful but an acute shift from any carbon source to another will lead to remodeling of the gene expression profile brought upon by growth regulatory and nutrient sensing pathways. The GC-content effect on transcription is only relevant when stability is inferred from steady state abundance measurements, not direct kinetic measurements. This is more directly examined in Zhou et al.'s paper, "Codon usage is an important determinant of gene expression levels largely through its effects on transcription". This is not directly referencing the Coller/Green methods. We have clarified this point in the text.

> \- Discussion section: This conclusion needs to be elaborated as it is not self-evident.

We have elaborated on this point in the text.

> Reviewer \#2:
>
> I agree with reviewer 1 that in an ideal world the authors would had employed an rRNA subtraction procedure such as ribo0, in addition to the total RNA analysis, as this would have allowed them to recover far more mRNA reads. Nonetheless, the data do argue strongly against the possibility that the discrepancies between the authors\' mRNA half-life data and previous studies was simply an artifact of looking at polyA selected mRNAs. This experiment and the expanded discussion thus address the major concern I had with the original submission.

Thank you and we concur that the analysis of total RNA further bolsters our original conclusions.

[^1]: These authors contributed equally to this work.
